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Abstract
 
Chemoresistance and metastasis are the main reasons for treatment failure in melanoma 
patients. MAPK pathway is often hyperactivated in melanoma due to BRAF mutations. BRAF 
and MEK inhibitors revolutionized the standard-care of patients with advanced melanoma. Yet, 
patients develop resistance to these drugs very fast.  
Previous studies showed that Tribbles homolog 2 (TRIB2) is overexpressed in melanoma and 
confers resistance to chemotherapeutic and targeted drugs such as darcarbazin, PI3K and 
mTOR inhibitors. Furthermore, TRIB2 protein contains a MEK1 binding site. Taking this into 
account, we hypothesize that TRIB2 might confer resistance to MEK inhibition. 
In order to test our hypothesis, we generated isogenic melanoma cell lines with TRIB2 
knockdown, using shRNA, and cells with TRIB2 depletion using CRISPR technique.  
Since the members of the Tribbles protein family might be functionally redundant and 
compensate for TRIB2 depletion, we decided to determine mRNA and protein levels of TRIB1, 
TRIB2 and TRIB3 using q-PCR and Western-Blot techniques, respectively, on a panel of 
melanoma and non-melanoma cell lines. We treated these isogenic cell lines with the MEK 
inhibitor Refametinib for 72h. The resistance was evaluated through cell death analysis, using 
cell counting based on trypan-blue and annexin V/ Propidium iodide staining. 
The isogenic cell lines were successfully established and determined that compensation of 
TRIB2 through TRIB1 or TRIB3 only plays a minor role.  Importantly Refametinib treatment 
of melanoma cell lines with different levels of TRIB2 showed that cell death correlated with 
TRIB2 expression level suggesting that TRIB2 confers resistance to MEK inhibitors. 
Understanding the resistance mechanisms to the therapeutic agents can improve the outcomes 
of current therapies and contribute to the development of new therapeutic approaches.  
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Resumo 
 
Melanoma é uma das formas mais agressivas do cancro da pele, sendo responsável por 80% 
das mortes para este tipo de cancro. Trata-se de um cancro é potencialmente metastático 
altamente resistente à terapia, levando a uma baixa taxa de sobrevivência. Existem duas vias de 
sinalização que estão comummente mutadas ou hiperactivas neste cancro, que contribuem para 
a proliferação celular e para a resistência a algumas terapias que atuam segundo as vias de 
sinalização PI3K e MAPK.  
A via-de-sinalização MAPK está frequentemente hiperactiva devido a mutação numa das 
serinas/treoninas kinases que compõem a via, BRAF. Vemurafenib foi o primeiro fármaco 
“alvo” aprovado pela FDA no melanoma, e sem dúvida revolucionou a terapia no melanoma. 
Trata-se de um inibidor do RAF, específico para a mutação V600E. Contudo, o melanoma é 
um cancro altamente heterogéneo e os pacientes eventualmente adquirem resistência a esta 
terapia. Por isso, têm se apostado no desenvolvimento de inibidores de MEK, que se localiza 
jusante de BRAF na via de sinalização. No entanto, os mecanismos de resistência continuam a 
ser das maiores preocupações, e das principais causas de morte nestes pacientes. Recentemente 
o nosso grupo identificou um novo mecanismo de resistência aos inibidores de PI3K/ mTOR, 
BEZ235, a inibidores de PI3K, BAY236, BAY439, inibidores do mTOR, Rapamycin e até 
mesmo a fármacos citotóxicos utilizados na quimioterapia (DTIC, gemcitabine and 5-
fluorouracil) mediado por TRIB2. TRIB2 é uma pseudokinase que pertence à família de 
proteínas Tribbles, constituída por três elementos: TRIB1, TRIB2 e TRIB3, altamente 
conservados e homólogos. Na sua estrutura, TRIB2 possui um domínio pseudokinase, um 
domínio COP1 e um domínio de ligação às proteínas MAPK. Este estudo em que foi 
identificado um mecanismo de resistência mediado por TRIB2, demonstrou que TRIB2 se liga 
ao AKT via domínio COP1 ativando o AKT através da fosforilação da serina 473. Uma vez 
fosforilado e ativo, o AKT fosforila MDM2, que regula a atividade de p53, sendo considerado 
um oncogene. Quando MDM2 está fosforilado, fosforila o p53 enviando-o para degradação, 
bloqueando assim os mecanismos apoptóticos mediados por p53. Os autores demonstraram 
ainda que o AKT, uma vez ativado, fosforila também FOXO3a, um gene supressor de tumores, 
enviando o para degradação. Estudos anteriores demonstraram que a proteína TRIB2 é 
sobreexpressa em linhas celulares de melanoma e também em pacientes com melanoma. 
Considerando estas três principais observações: (a) TRIB2 na sua estrutura tem um domínio de 
ligação MAPK, (b) TRIB2 está sobreexpressa em Melanoma e (c) TRIB2 confere resistência 
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aos inibidores de PI3K e mTOR, levantamos a hipótese de que TRIB2 confere também 
resistência a inibidores de MEK. 
TRIB2 pertence à família de proteínas tribbles que são altamente conservados entre espécies e 
apresentam alta homologia, podendo ter funções redundantes. Deste modo, antes de testarmos 
a nossa hipótese, decidimos averiguar os níveis de mRNA, através de q-PCR, e de proteína, 
através de um western blot, dos diferentes tribbles em linhas celulares de melanoma (G361, 
SK-Mel-28 e A375), osteossarcoma e HEK293T. Os resultados mostram que os níveis de 
mRNA de TRIB1 e TRIB2 são maiores em linhas celulares de melanoma comparativamente às 
linhas HEK293T e osteossarcoma, enquanto os de TRIB3 são mais elevados na linha celular 
HEK293T em relação às linhas celulares de melanoma e a de osteossarcoma. Os resultados de 
expressão de proteína mostram que todas os membros da família Tribbles são mais expressos 
nas linhas celulares de melanoma comparativamente às linhas celulares de Osteossarcoma e 
HEK293T.  
Para testar a nossa hipótese criámos dois sistemas diferentes em linhas celulares de melanoma: 
uma linha celular com níveis de expressão de TRIB2 mais reduzidos (knockdown) através de 
shRNA; outro onde eliminamos a expressão de TRIB2 utilizando a técnica CRISPR-Cas9.  Para 
obtenção de knockdowns para TRIB2 transfetámos um plasmídeo que codifica com shRNA 
que codifica para TRIB2que é depois processado a small interference (si)RNA, e liga-se ao 
mRNA específico promovendo a sua degradação. O knockdown foi conseguido na linha celular 
G361. Nas restantes (SK-Mel-28 e A375) o controlo da técnica, shGFP interferiu também com 
a expressão de TRIB2. A técnica de CRISPR Cas9 baseia-se o sistema imune de E. coli: este 
sistema é constituído por single-guide RNA (sgRNA) e pela Cas9, uma nuclease que reconhece 
a sequência especifica e causa quebras duplas no DNA, que são depois corrigidas pelo sistema 
de reparação de material genético NHEJ levando a pequenas inserções ou deleções, culminando 
na perda de função do gene alvo. As células foram transfetadas com um plasmídeo que codifica 
para sgRNA e também para a Cas9. Foram testados vários clones para a obtenção de TRIB2 
knockouts (KO), apenas uma parte está representada neste trabalho. Optámos por utilizar um 
KO de SK-Mel-28 (#8) e um de G361 (#14).  Estas duas técnicas já tinham sido previamente 
validadas no nosso laboratório.  
O processo de obtenção de linhas celulares é bastante moroso, por isso decidimos otimizar 
algumas condições para depois testarmos a nossa hipótese de que TRIB2 confere resistência à 
inibição de MEK. Testámos duas concentrações para o inibidor de MEK (Refametinib) 100nM 
e 1µM onde é possível observar que ambas as concentrações inibem a via de sinalização e 
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induzem morte celular. Optámos por usar as duas concentrações visto que utilizamos diferentes 
linhas celulares que se comportam de maneira distinta. Testámos também períodos curtos e 
longos de exposição ao fármaco, e verificámos que após 72 horas a via ainda está inibida. Deste 
modo, optámos por este período de incubação pois facilita a análise da morte celular. Testámos 
também plaquear diferentes números de células, para ter a certeza que estas não morriam por 
falta de espaço, mas sim devido ao inibidor, e observámos que o número de células plaqueadas 
não exerce influência na morte celular. Decidimos também averiguar qual o melhor tempo de 
incubação do controlo positivo para morte celular (etoposide) onde verificámos que 48horas de 
incubação causa mais morte celular. 
Após a obtenção das linhas celulares, as células foram submetidas ao tratamento com um 
inibidor de MEK, Refametinib, durante 72 horas. A morte celular foi avaliada através de 
contagem de células com trypan blue (células mortas surgem com citoplasma azul), através da 
técnica Annexin V / Propidium Iodide (PI), um método para identificar as células em apoptose 
que se baseia na integridade da membrana celular (as células em apoptose apresentam 
mudanças na morfologia da membrana celular que permite a estes componentes se ligarem aos 
alvos e emitir fluorescência) e apenas com PI. As técnicas Annexin V/PI e apenas marcação 
com PI foram analizadas no aparelho FACs Calibur utilizando o programa CellQuestPro. Todos 
os dados foram tratados/ analisados utilizando GraphPad Prism6. Os nossos resultados mostram 
que a morte celular se correlaciona com os níveis de expressão de TRIB2: nos vários sistemas 
utilizados, as células com reduzida ou sem expressão de TRIB2 morreram mais que as que 
tinham TRIB2, sugerindo que esta proteína pode, de algum modo, conferir resistência à inibição 
do MEK.  
Em suma, este trabalho mostra evidencias que sugerem que TRIB2 confere resistência à 
inibição do MEK tornando TRIB2 um alvo importante na terapia do melanoma. Estudos 
anteriores sugerem TRIB2 como um biomarcador no Melanoma, uma vez que este prediz a 
resposta clinica a uma dada terapia. Neste estudo demonstramos evidências que TRIB2 confere 
também resistência à inibição do MEK e que poderá ser útil no futuro, para diferenciar os 
doentes que poderão beneficiar da terapia. Um estudo aprofundado dos mecanismos de 
resistência aos fármacos contribui para o desenvolvimento e melhoria das terapias, aumento a 
esperança de vida dos doentes oncológicos. 
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1. Introduction 
 
1.1 Cancer 
Cancer is among the leading causes of death worldwide. In 2013 there were 14.9 million of new 
cancer cases and 8.2 million deaths worldwide. Cancer incidence has been increasing in most 
countries since 1990. By 2030 it is expected 21.7 million new cases and 13 million cancer 
deaths (1, 2). Genetic differences and environmental factors, including infectious agents, 
lifestyle and culture, such as smoking, dietary patterns, sun exposure, physical inactivity and 
reproductive behaviors have been known to be the major risk factors for cancer (3-5).  
Cancer is usually viewed as an evolutionary process that results from the accumulation of 
mutations (usually somatic mutations) or epigenetic events (which do not alter DNA sequence, 
conferring a selective growth advantage and ultimately uncontrolled proliferation (6). There are 
two major types of mutations: the hereditary that arise on a germ cell (7, 8) and somatic 
mutations that occur in any non-germ cell. The latter include base pair substitutions, small 
insertions or deletions, chromosomal rearrangements and gain or losses of gene copy number. 
Tumorigenesis is a multi-step process that can arise from the alteration in three main types of 
genes: oncogenes with dominant gain of function: genes that stimulate cell division, inhibit cell 
differentiation and halt cell death; tumor suppressor genes loss-of-function: genes that inhibit 
cell proliferation and regulate apoptosis; and DNA repair genes (9, 10). Traditionally, the 
accumulation of genetic mutations has been considered the major cause of cancer progression. 
However, this paradigm has changed and is currently accepted that epigenetic changes also play 
an important role in cancer development (11).  
After centuries of research it is now established that cancer is a very complex group of diseases. 
In 2001 Hanahan and Weinberg described for the first time “rules that govern the transformation 
of normal cells into malignant cancers”, known as the “hallmarks of cancer”.  These hallmarks 
can be defined as a small number of molecular, biochemical and cellular characteristics shared 
by most of all human cancer (12, 13). The first six hallmarks of cancer described were 
(figure1.1): self-sufficiency in growth signals, insensitivity to anti-growth signals, limitless 
replicative potential, sustained angiogenesis, evading apoptosis and tissue invasion and 
metastasis (12). In 2011, Hanahan and Weinberg purposed two new hallmarks essential for 
malignant transformation: genomic instability which confers tumor heterogeneity and 
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inflammation which is believed to foment multiple hallmarks functions. There are two more 
capabilities emerging: a reprograming metabolism and avoid immune destruction (13). 
 
  
Figure 1.1. The hallmarks of Cancer. Almost every cancer has acquired some capabilities 
during its development. The first 6 hallmarks of cancer suggested in 2000 were: sustaining 
proliferative signaling, reducing their dependence on growth factors from normal tissue 
microenvironment, evading growth suppressors, resisting cell death, allowing cells to 
proliferate out of control, angiogenesis in order to obtain oxygen and nutrients, immortality and 
invasion & metastasis mainly due to morphological cell changes and activation of 
metalloproteases. In 2011, the same authors suggested 2 new hallmarks of cancer involved in 
cancer pathogeny: genomic instability that allows cancer cells with driver mutations to 
proliferate and gives rise to tumor heterogeneity and tumor promoting inflammation that can 
support and enhance the other capabilities. New capabilities are emerging:  one of them involves 
the ability of cancer cells to reprogram its metabolism in order to sustain neoplasic proliferation 
and the other involves the ability to avoid immune system mediated destruction. Adapted from 
Hanahan D. and Weisenberg R., Cell 2011. 
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1.2 Melanoma 
Melanoma is the most dangerous form of skin cancer and represents less than 5% of all skin 
cancers, yet is responsible for 80% of skin cancer deaths (14). Metastatic melanoma has a poor 
clinical outcome, about 5% after six months. The World Health Organization (WHO) estimates 
that each year are diagnosed 132,000 of new cases of melanoma. The International Agency for 
Research on Cancer (IARC) estimates that in Europe there is 100,000 new cases and 22,000 
deaths each year (15-17).  
Melanoma is a cancer that arises from melanocytes, which are specialized pigmented cells 
(figure 1.2), derived from the neural crest and are found predominantly in the skin and hair 
follicles. A major risk associated with melanoma is the ultraviolet radiation (UV), along with 
the family history, fair skin and immunosupression. Melanoma has a high somatic mutation 
rate, among the highest of any cancer type, largely attributed to UV radiation (18). In response 
to UV radiation, keratinocytes, which are cells that secrete the major structural components of 
the epidermal barrier, synthesize factors that regulate melanocyte survival, differentiation, 
proliferation and motility. In this way, keratinocytes stimulate melanocytes to produce melanin 
resulting in the tanning response. When exposed to UV radiation, melanocytes are activated 
and secrete melanin and protect the neighboring cells from further damage (15, 18-21). 
Increased survival features of melanocytes depend not only on themselves, but also on paracrine 
stimulation from fibroblasts and keratinocytes. Melanocytes can escape their regulation by 
keratinocytes through disrupted intracellular signaling due to mutations in growth regulatory 
genes, production of autocrine growth signals and loss of adhesion receptors. Therefore, 
melanocytes can proliferate and spread, leading to the formation of a naevus (a pre-malignant 
lesion) (15, 21). 
Melanoma is highly metastatic, and highly resistant to treatment (22-24). As mentioned before, 
melanocytes derived from neural crest cells. These cells undergo epithelial-mesenchymal-
transition (EMT) in order to migrate and exit from the neural tube. In a similar way, melanoma 
cells are able to undergo EMT in the initial events of metastasis to dissociate from surrounding 
keranocytes (22). In fact, metastasis are the main cause of the death in melanoma patients (25). 
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1.2.1 Melanoma Classification 
 
Melanoma can be categorized into five different stages according to their tumor thickness, 
number of metastatic nods and distant metastasis (figure 1.3). The first stage, stage 0 is the less 
aggressive one, when cell proliferations is limited to the epidermis and has not reached the 
underlying dermis. In these stage the treatment applied is surgical resection. Melanomas in 
stage I and II differ on tumor thickness and ulceration and are treated by surgical resection 
followed by drug or radiation treatment. When melanoma spreads to the lymph nodes is 
classified as stage III. In this case surgical removal of the lymph nodes is required. Stage IV 
refers to a cancer that has spread into distant organs, and it is treated with chemotherapy. 
According to American Joint Committee on Cancer (AJCC), Melanoma can be clinically 
categorized in 5 different subtypes including: superficial spreading melanoma, amelanotic 
melanoma, nodular melanoma, acral lentiginous melanoma, and uveal melanoma (table 1.1) 
(15, 18, 21, 26-29). 
  
Figure 1.2. Anatomy of the normal skin. Melanocytes are specialized pigmented cells that 
produce melanin and reside in the basal layer of human skin. Adapted from National Cancer 
Institute, 2017. 
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Subtype Description Frequency Common Site 
Superficial 
Spreading 
Melanoma 
Form of melanoma in which 
cancer cells tend to stay within 
the tissue of origin:  epidermis. 
 
70 % Trunk of men 
Legs of Women 
Amelanotic 
Melanoma 
Type of skin cancer in which 
the cells do not produce 
melanin, they have lack of 
pigment. 
2-8 % Glabrous skin 
(skin that is 
normally devoid of 
hair) 
Nodular melanoma Melanoma cells proliferate 
downwards through the skin 
(vertical growth). 
10-25% Trunk of men 
Legs of Women 
Acral Lentiginous 
Melanoma 
Form 
of melanoma characterized by 
its site of origin: palm, sole, or 
beneath the nail. 
5% Palms 
Soles 
Nails 
Uveal Melanoma Melanoma of the eye. 3-5% Iris, ciliary body or 
choroid 
Table 1.1- Clinical Classification of Melanoma. Adapted from Chudnovsky Y. et al, JCI 
2005. 
Figure 1.3. The four stages of Melanoma. Melanoma is staged depending on tumor thickness, 
number of metastatic nodes and distant metastasis. Stage 0-II is confined to the epidermis, 
stage III includes lesions spread to the lymph nodes and on stage IV the lesions spread to other 
organs. Adapted from Colegio Oficial de Enfermeros de Badajoz, 2017. 
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1.2.2 Melanoma Genetics 
The MAPK signaling cascade plays a key role in melanoma, making it an important therapeutic 
target. In normal cells, the MAPK pathway (figure 1.4) is activated by mitogens or hormones 
and extracellular growth factors. This signaling pathway controls fundamental cellular 
processes such as growth, proliferation, differentiation, migration and apoptosis (30, 31). The 
MAPK pathway includes a small G protein (RAS) and three serine/threonine protein kinases: 
B- type RAF kinase (RAF), Mitogen-activated protein kinase kinase (MEK) and Extracellular 
signal-regulated kinase(ERK). The binding of mitogens, hormones, cytokines or 
neurotransmitters to tyrosine kinase receptors causes its dimerization, which triggers the 
activation of RAS. Mechanistically, the phosphorylated SH2 (Src Homology 2) of GRB2 
(Growth factor receptor-bound protein 2), an adaptor protein, brings Son of Sevenless (SOS) 
into close proximity to GDP-Ras and converts it into Guanosine-5'-triphosphate (GTP) -Ras 
(activated form) by catalyzing the GDP to GTP (32). This guanine nucleotide exchange leads 
to the activation of RAS signaling. Once activated, RAS attracts and binds RAF, which usually 
is found in cytosol, via effector loop. Therefore, RAF becomes attached to the membrane via 
RAS. In this way, RAF becomes activated and is able to activate a second kinase, MEK, by 
phosphorylating its serine / threonine domains (33). MEK is considered a “dual specificity 
kinase”, which means that it is able to phosphorylate serine/ threonine residues as well as 
tyrosine residues. By phosphorylation, MEK activates ERK1 and ERK2 that, once activated, 
each of these ERKs phosphorylates downstream substrates regulating several cellular processes 
(33). The activation of MAPK signaling potentiates PI3K signaling. These pathways can 
interact at different levels creating a complex network. The resulting signaling cascade 
culminates with translocation of ERK to the nucleus where it activates transcription factors, 
resulting in gene expression (15, 17, 32, 34, 35). Some transcription factors activated by ERK 
are cdc25 (phosphatase), MSK1/2 (stress activated kinases) and CREB. Once activated, these 
transcription factors regulate cell proliferation and survival (36, 37). Most cancer lesions that 
lead to constitutive activation of ERK signaling occur during the early steps of tumorigenesis. 
The constitutive activation of ERK signaling can result from the overexpression of receptor 
tyrosine kinases (RTKs), activating mutations in receptor tyrosine kinases, sustained autocrine 
production of activating ligands, RAS mutations and BRAF mutations (38).  
MAPK and PI3K pathways are key regulators of cell proliferation in melanoma. The 
most common mutation found in melanoma is in BRAF (~50%) (39, 40),  followed by 
Phosphatase and tensin homolog  ( PTEN) (30-50%) (41) and NRAS mutations (10-20%), 
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figure 1.4 (39, 42). AKT3 is activated in ~60% of melanomas, due to its overexpression or 
alterations in upstream regulators such as PTEN (43). BRAF and NRAS mutations can result in 
hyperactivated ERK, which is present in up to 90% of human melanomas (26). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.3 Melanoma Treatment 
 Until 2010 the standard care for metastatic melanoma included surgical resection, 
chemotherapy and high interleukine 2 (IL-2) doses (figure 1.5) (17). When detected early, 
melanoma can be treated by surgical resection, which has over 95% success rate at stages I/II 
(44). If detected in advanced stages, melanoma is difficult to treat since currently there is no 
effective treatment. Melanoma lesions can be asymptomatic for long periods, or be detected at 
stage IV without a clearly identified primary lesion. The main drugs used in melanoma patients 
are chemotherapy, immunotherapy and targeted therapies (table 1.2). Despite all the efforts, 
melanoma is still one of the most aggressive cancers, with extremely poor prognosis (21, 44, 
45).  
 
Figure 1.4. The MAPK signaling pathway.  Growth factors bind to the tyrosine kinase 
receptor, which brings SOS into close proximity. GDP-RAS is converted into GTP-RAS and 
phosphorylates RAF. RAF phosphorylates MEK, and MEK phosphorylates ERK. ERK 
translocates into the nucleus and stimulates transcription of target genes.  Mutations in NRAS 
are found in ~20% of melanoma patients. MAPK pathway is frequently activated by mutations 
on BRAF (~50%). The PI3K pathway can be activated due to PTEN mutations (30-50%) or 
AKT mutations (~30% in AKT3).   
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surgical Resection 
Surgical resection is still the first treatment choice for patients with early stages melanoma 
having huge success rate in stage I/II. In cases of metastatic melanoma, surgical resection has 
a minimal impact in treatment (44, 46). The treatment choice for melanoma patients in stage I-
III is surgery. An important prognostic indicator, which provides information about disease 
progression independently of the treatment, is the analysis of sentinel lymph node (SNL), the 
first node draining the primary melanoma in the lymphatic system (47). The first rout of 
metastasis in melanoma is the lymphatic system, making the study of SNL an important toll 
because it allows the detection of locoregional dissemination (46, 47). If melanoma is spread 
to the SLN it is performed a complete lymphadenectomy as a gold standard treatment in order 
to remove metastatic cells present in the lymphatic drainage (48). 
 
 
 
  
Figure 1.5. Treatment applied in metastatic melanoma. Dacarbazine was the first 
chemotherapeutic drug used, followed by high doses of Interleukine 2 (IL-2). After 2010 new 
therapeutic strategies became available such as immunotherapies (exp. Ipilimumab, 
Nivolumab) and targeted therapies (examples: Vemurafenib and Trametinib). Adapted from 
Sullivan EJ et al, CCR 2013. 
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 Drug Group Drug Class Examples Effects 
C
H
E
M
O
T
H
E
R
A
P
Y
 
Alkylating 
Agentes 
Nitrosaureas 
Fotemustine/ 
Carmustine 
SsDNA breaks 
Nitrogen Mustards Cyclophosphamide DNA crosslinking 
Triazenes 
Dacarbazine/ 
Temolozomide 
 
Inhibition of nucleic 
acid and protein 
synthesis 
Antibiotics 
Anthracyclines 
 
Doxorubicin 
(adriamycin) 
SsDNA breaks 
DNA crosslinking 
Inhibition of DNA 
and RNA replication 
Plant-derived 
products 
Vinca Alkaloids Vincristine 
Altered cell division, 
motility 
Taxanes  Taxol 
Altered cell division, 
motility 
Hormonal 
Analogs 
Antiestrogen Tamoxifen 
Altered estrogen 
signaling 
Platinium 
Drugs 
 Cisplatin 
SsDNA and dsDNA 
breaks 
IM
M
U
N
O
T
H
E
R
A
P
Y
 
Cytokines  IL-2 
Growth and 
activation of T-cells 
and natural killers, 
promoting tumor 
regression 
Checkpoint 
inhibitors 
 
Ipilimumab (antibody 
against CTLA-4) 
Promotes T-cell 
activation and 
proliferation ; 
amplifies T cell 
immunity 
 
Nivolumab / 
Pembrolizumab  
( antibodies against PD-
1) 
Promotes T cell 
activation, IL-2 
production and 
mediates immune 
toxicity 
T
A
R
G
E
T
E
D
 
T
H
E
R
A
P
IE
S
 BRAF 
inhibitors 
 
Vemurafenib (against 
V600E mutation) 
Anti- proliferative 
effects 
MEK 
inihibitors 
 Trametinib 
Induces cell cycle 
arrest and reduces 
tumor growth 
Table 1.2. Drugs used in melanoma.  
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Chemotherapy 
Cytotoxic chemotherapy has been used for the treatment of metastatic melanoma for the last 
decades. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which 
is a characteristic of cancerous cells, but it is also a characteristic of normal cells with fast 
proliferation rates, such as the bone marrow, skin cells, gastrointestinal tract cells and hair 
follicles cells. The fact that chemotherapeutic agents non-specifically target cells that are 
dividing rapidly is the major reason for their toxicity (49-52). The first chemotherapeutic agent 
used to treat advanced melanoma was dacarbazine (DTIC), an alkylating agent (figure 1.5). The 
alkylating agents are the most widely used anti-cancer drugs and have the ability to covalently 
bind an alkyl group to the DNA bases (commonly to the N7 guanine) forming an adduct, 
thereby preventing multiplication of rapidly growing cells. DTIC has an overall response rate 
ranging between 10-20% and only allow a complete remission on 5% of patients (21, 53, 54). 
Temozolomide (TMZ) is another alkylating agent widely used in melanoma that has some 
advantages over many alkylating agents because of its unique chemical structure and 
pharmacokinetic properties. In particular, its small weight allows the compound to cross the 
blood brain barrier. This drug has shown efficacy in the treatment of malignant brain tumors 
and metastatic melanoma in the brain (55, 56). Other cytotoxic chemotherapeutic drugs have 
been tested such as nitrosaureas (Carmustine), vinka alcaloides (Vincristine), taxanos (Taxol) 
and platinium compounds (Cisplatin) (table 1.2) but they had no better results than DTIC (21, 
53, 54). Another nitrosourea used is Fotemustine, which was proven to be efficient, mainly in 
brain metastasis giving its high lipophilicity (57). Other conventional chemotherapeutic drugs 
have also been used to treat melanoma, such as plant-derived products, antibiotics and hormonal 
analogs (table 2). Alkylating agents, along with most other cytotoxic agents, are not “magic 
bullets” envisioned by Paul Erhlich: drugs that go straight to their intended cell-structural 
targets. The resistance to conventional chemotherapeutic agents in melanoma leads to an 
extremely poor prognosis (21, 53, 54, 58-63).  
 
The scientific progress during the last decades, allowed for a deeper study of molecular 
mechanisms driving melanoma progression, leading to an improvement in melanoma treatment. 
Since the last decade two new therapeutic approaches improved the standard care for melanoma 
patients: Immunotherapies and targeted therapies (17, 64).   
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Immunotherapy  
Melanoma is a highly immunogenic type of cancer, and melanocytes have the ability to induce 
adaptive immune responses. The primary effector cells of the adaptive immune response against 
cancer are the T lymphocytes that include helper T cells and cytotoxic T lymphocytes (65, 66). 
The ability of melanoma cells to induce adaptive immune responses was associated with the 
fact that melanoma has a high mutation load that leads to the presentation of immune 
stimulatory neoantigens. Neoantigens are antigenic proteins that have new epitopes that have 
not been previously exposed / recognized by the immune system, leading to an immune 
response (67-69).  The statement that melanoma is highly immunogenic is supported on several 
observations: (a) spontaneous remissions occur; (b) in about 5% of the melanomas the primary 
tumor is not found; (c) it was found that primary tumor and metastasis have infiltrated 
lymphocytes; (d) studies demonstrated that tumor infiltrating T lymphocytes can recognize 
some melanoma antigens; (e) melanomas respond to immunotherapy. In cases of 
immunosuppression the risk of developing melanoma is higher (70). Immunotherapy is defined 
as the use of the immune system to treat cancer (71, 72). Immunotherapy, including cytokine 
and vaccine treatments are an alternative to conventional chemotherapeutic drugs (73). One of 
the first “immunotherapeutic tools” used was IL-2, started in the 90’s. Initial studies revealed 
that IL-2 is able to induce tumor regression in melanoma and other malignancies (65). Yet, IL-
2 has shown some degree of toxicity mainly associated to vascular leak syndrome (VLS) (65). 
VLS is a phenomenon characterized by an increased vascular permeability along with protein 
and fluid extravasation, resulting in interstitial edema and organ failure (74). Recently, three 
new immunotherapeutic drugs have been approved by the FDA to treat melanoma: Ipilimumab, 
an antagonist monoclonal antibody to CTLA-4 (approved in 2011), (figure 1.6) Pembrolizumab 
and Nivolumab. Pembrolizumab and Nivolumab are both antagonist monoclonal antibodies to 
PD-1 and were approved in 2014 (65, 73, 75). Immune checkpoints are negative regulators of 
the immune system, important to maintain self-tolerance and avoid an auto-immune response. 
Melanoma cells can take advantage of this mechanism and block an immune response against 
them. The anti-CTLA-4 antibody binds to CTLA-4 receptor blocking CTLA-4 signaling. This 
blockade contributes to T cell activation and proliferation, amplifying T cell mediated immunity 
against melanoma cells (76). Similar to CTLA-4, PD-1 is also a checkpoint inhibitor, playing a 
key role in immune tolerance.  In cancer cells, PD-1 interaction with its ligand promotes T cell 
apoptosis limiting T cell proliferation and inhibiting IL-2 production. The PD-1 pathway 
blockade induces T cell activation and proliferation, enhancing anti-tumoral activity (70, 77). 
However, these therapies have an extremely high cost, and do not benefit the majority of the 
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patients. In fact, the immunotherapy is only beneficial to 15- 50% of melanoma patients. Some 
patients have intrinsic resistance in tumor cells that have genetic or non-genetic changes that 
contributes to natural cell survival. One example is that tumors can express proteins with few 
molecular exchanges, making the immune system unable to recognize these antigens as foreign. 
It is also possible that, with tumor development, cancer cells lose a proportion of its non-silent 
mutations, producing lower ratio of antigenic epitopes leading to a phenomenon called the 
immunoadaption of tumors. Moreover, cancer cells have developed mechanisms to escape the 
immune system resulting in a less efficient therapy (14, 64, 70-72, 74). Another promising 
strategy is the use of this dual inhibition combined with immunotherapy including IL-2, 
interferon, anti-CTLA4, anti-PD1 (78, 79). The future of immunotherapies includes the 
understanding of resistance mechanisms and the development / improvement of biomarkers in 
order to provide information about the patient response to the treatment. Hopefully, the ability 
to distinguish patients that may benefit from these treatments may improve the clinical outcome 
of melanoma patients (37). In the past few years much attention has been focused on the 
development of targeted therapies (17, 64). 
 
 
 
 
 
 
 
 
  
 
 
  
Figure 1.6. Immune checkpoint blockade in Melanoma. Ipilimumab (against CTLA-4) 
blocks the immunosuppression induced by the interaction between the B7 family and CTLA-
4 proteins. Nivolumab or Pembrolizumab (against PD-1) blocks the interaction of PD-L1 
ligand to its receptor. The inhibition of these immune checkpoints allows the immune system 
to target cancer cells. 
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Targeted Therapies 
Over the past years a new generation of cancer treatment arose, such as targeted therapies. 
Targeted therapies interfere with disease-specific proteins involved in tumorigenesis (49, 50, 
80). Target-based therapies are considered to be the future of cancer treatment and much 
attention has been focused on developing inhibitors for MAPK signaling pathway. MAPK 
pathway is often hyperactivated in melanoma due to BRAF and NRAF mutations (two thirds of 
melanomas) (15, 18, 38).  
Deregulation of the MAPK pathway, described in section 1.2.2, is frequent in melanoma 
leading to increased cell proliferation, invasion, metastasis and angiogenesis, making this 
pathway an important target in melanoma treatment. Despite recent therapeutic advances in the 
treatment of advanced melanoma, targeting RAS has not been so successful. NRAS mutations 
are commonly found in codon 12, 13 and 61 and have been associated and aggressive clinical 
which is easy to understand since active RAS can activate both MAPK and PI3K pathways 
leading to tumor progression and cancer cell survival. Although much effort has been made to 
target NRAS, to date no effective anti- RAS therapies have been successfully developed. 
Previous strategies were focused mainly in posttranslational modifications of NRAS using 
farnesyltransferase inhibitors. Nowadays the efforts are focused on targeting NRAS with small 
molecules or siRNA and mainly on downstream effectors of NRAS (81-83).  BRAF, one of the 
downstream effector of NRAS, is one of the three human RAF genes (together with A-RAF and 
C-RAF) and it is one of the most common mutated genes in melanoma ~50%. The most 
common mutation leads to a substitution of a glutamic acid for a valine at position 600 (V600E). 
The mutant V600E BRAF protein results in increased kinase activity (10 fold more activity) 
which induces hyperactivity of MAPK pathway, stimulating proliferation, survival and neo-
angiogenesis by stimulating autocrine vascular endothelial growth factor (VEGF), contributing 
to the development of nevi. Some studies have shown that V600E BRAF regulates expression 
of IL-8 a pro-inflammatory chemokine to promote tumor growth and angiogenesis. This mutant 
form also induces metastasis by triggering invasive cellular behavior and by promoting IL-8 
mediated anchoring of melanoma cells to the vascular endothelium, which helps cell 
extravasation and the development of lung metastasis. As mentioned before, the most common 
gene mutated in melanoma is BRAF. Patients with BRAF mutations were associated with a 
poor prognosis. (15, 32, 38, 84). Sorafenib is a nonselective inhibitor of tyrosine kinases (like 
BRAF) and RTKs such as vascular endothelial growth factor receptor (VEGFR) and was the 
first BRAF inhibitor investigated in clinical trials in melanoma (38). Clinical trials using 
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sorafenib as a monotherapy failed to demonstrate anti-tumor activity (85). Studies using 
sorafenib along with other therapeutic agents such as DTIC, carboplatin and paclitaxel in 
patients with metastatic melanoma were also clinically ineffective. (85-88). The limited activity 
of sorafenib in tumors with BRAF mutations contributed to the development of new inhibitors 
with greater selectivity such as Vemurafenib. This inhibitor was the first molecularly targeted 
therapy approved by the FDA in 2011 for the treatment of advanced melanoma (89). This drug 
has shown potent anti-proliferative effects in several preclinical models, including the ones 
harboring the V600E mutation. The mechanism of action involves selective inhibition of the 
mutated BRAF V600E kinase, which leads to reduced MAPK signaling activity. A phase III 
clinical trial comparing Vemurafenib and DTIC as first line therapy showed that Vemurafenib 
improved overall and progression-free survival compared to DTIC group. However, were 
detected some adverse effects associated with Vemurafenib such as arthralgia, rash, fatigue, 
alopecia, photosensitivity, nausea and diarrhea. In fact, there are some cutaneous adverse effects 
described in 92-95% of melanoma patients treated with BRAF inhibitors. There are also some 
benign and malignant lesions associated with Vemurafenib treatment, being the most commons 
squamous cell carcinoma and keratocanthoma (73, 84, 89, 90). The mechanism behind the 
neoplasia development points to MAPK re-activation in skin with mutated RAS.  BRAF 
inhibitors activate C-RAF in wildtype cells, that can induce ERK signaling, leading to 
squamous cell carcinoma development. Some of the patients treated with Vemurafenib also 
developed basal cell carcinoma (84, 91). The major problem / concern using Vemurafenib (and 
also other inhibitors) is that patients eventually develop resistance to therapy, leading to a poor 
prognosis. Actually, there are already some resistance mechanisms associated with BRAF 
inhibitors such as re-activation of MAPK signaling, changes in ERK1/2 regulated cell cycle 
events, activation of alternative signaling pathways and chromatin-regulating events (92). Re-
activation of MAPK signaling can emerge due to mutations on RAS, which promotes C-RAF 
dimerization and activation and due to ERK mutations. In fact, a study has demonstrated that 
elevated expression of C-RAF was associated with a mutant BRAF melanoma cell resistance 
to AZ628, a RAF inhibitor (92-94). Herkert B. et al., also showed that ~40% of melanoma 
patients with BRAF mutations have concomitant loss of PTEN, contributing to the 
hyperactivation of PI3K pathway and consequently to cancer cell survival (95-97) . 
 Vemurafenib revolutionized the standard care of melanoma patients. Yet, a big part of 
melanoma patients dies from resistance once drugs stop having a clinical effect. An intrinsic 
mechanism of resistance to Vemurafenib is the expression of Hepatocyte growth factor (HGF), 
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which leads to increased cell proliferation (98). Acquired resistance mechanisms were also 
described such as upstream mutations on NRAS, downstream mutations of MEK and BRAF 
splice variants.  Considering these complications, an alternative strategy is the development of 
inhibitors for downstream effectors of BRAF, such as MEK (99-103).  
Nowadays, selective MEK inhibitors represent a promising new therapeutic option in BRAF 
and NRAS mutated melanomas. Some studies demonstrate that preclinical models with BRAF 
mutations are sensitive to MEK inhibitors. Patients harboring NRAS mutations were found to 
be partially sensitive to MEK inhibitors (104, 105). In BRAF mutated melanoma murine 
xenografs, MEK inhibitors contributed to tumor regression through increased apoptosis and 
reduced angiogenesis and proliferation (104, 106) The first MEK inhibitor, PD098059, was 
described in 1995  (104, 107, 108). Until now, about thirteen MEK inhibitors have been tested 
in the clinic. The first MEK inhibitor approved by FDA in 2013 was Trametinib 
(GSK1120212), a selective inhibitor of MEK1 and MEK2 (100, 104, 108). MEK inhibitors can 
be classified in two major classes: Adenosine Triphosphate (ATP) competitive or non-ATP 
competitive inhibitors (108). The ATP competitive inhibitors bind to the ATP binding site of 
MEK, preventing MEK to be phosphorylated. E6201 is an ATP-competitive MEK inhibitor 
that proved to be effective against Vemurafenib resistance melanoma harboring a MEK1 
mutation in a preclinical model (109). However, the sensitivity to E6201 was correlated to 
wildtype PTEN suggesting that parallel signaling of PI3K pathway may play a role in resistance 
to this inhibitor (110). Most of MEK inhibitors are non-ATP competitive, which means that 
they bind to an allosteric binding site close to the ATP binding site preventing MEK activation. 
MEK 1 and 2 are very similar and consists in a N-terminal sequence, a kinase domain and a C-
terminal sequence. In the N-terminal sequence MEK1/2 contains an inhibitory/allosteric 
segment, which is only present in MEK1/2 and not in the other MAPKK. This allosteric 
segment present in MEK1/2 is relatively unique making the ATP non- competitive MEK 
inhibitors highly specific (108, 111). Trametinib is an orally available, small molecule, non-
ATP competitive MEK inhibitor that induces cell cycle arrest, reducing tumor grow. It was 
proven to be clinically effective in the presence of BRAF and NRAS mutations. Therefore, it 
was accepted by the FDA as a single agent for the treatment of patients with V600E BRAF and 
in combination with dabrafenib (104, 112). Refamatinib is a non-ATP competitive MEK 
inhibitor very similar to Trametinib, which is still in clinical trials (108). Another MEK inhibitor 
approved by FDA in 2015 for the treatment of advanced melanoma is Cobimetinib in 
combination with Vermurafenib. Cobimetinib is also an ATP non-competitive MEK 1/2 
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inhibitor (113, 114). Although all the efforts in developing an effective treatment, resistance to 
therapy is still the most difficult issue to be overcome. Patients develop resistance to almost all 
drugs, including to MEK inhibitors, such as the mutation MEK1 P124L (the substitution of a 
leucine by a proline), resulting in a gain-of-function mutation. Mutations on ERK were also 
associated with MEK inhibitors resistance leading to MAPK hyperactivation (94, 115-117). 
Another resistance mechanism is the activation of PI3K pathway. It was already shown that 
PI3K and MAPK pathways interact in order to regulate several cellular processes like cell 
proliferation and apoptosis. The MAPK pathway cross-activates PI3K signaling through 
regulation of PI3K, Tuberous Sclerosis Complex 2 (TSC2) and mTORC1. GTP-RAS can bind 
and activate directly PI3K kinase.  When RAS or PTEN are mutated, even in the presence of a 
MEK inhibitor, the PI3K pathway remains active contributing to tumor growth. Taking this into 
account, the inhibition of both PI3K and MAPK pathways might be used to more efficiently 
treat melanoma patients. Nowadays, there are several fair options for melanoma treatment. Yet, 
there are still significant obstacles to be overcome, like resistance mechanisms, that should be 
treated as a priority in melanoma care (32, 118, 119). 
 
1.2.4 Resistance mechanisms 
Understanding the mechanisms underlying the resistance associated with different therapeutic 
agents can improve the outcome of current therapies and contribute to the development of new 
therapeutic approaches. As mentioned before, one of the biggest concerns in melanoma is the 
development of resistance to treatment. Resistance can be intrinsic, meaning that it exists 
before the treatment or acquired when the resistance occurs after the treatment, which means 
that the tumor was initially sensitive to the treatment. There are some acquired resistance 
mechanisms already described, such as mutation on drug target / pathway, drug inactivation, 
drug efflux pumps, DNA damage repair, activation of alternative pathways, tumor 
heterogeneity and one of the most commons, defects in cell death control (figure 1.7) (120-
122). 
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Most of the anti-cancer drugs must undergo metabolic activation in order to have a clinical 
effect. The toxicity to the normal tissues is a limiting factor to the amount of drug that can be 
administered. The amount of drug that reaches the tumor mass is also limited by the drug 
pharmacokinetics (absorption, distribution, metabolism and elimination) (121). Cancer cells 
can develop resistance to the treatments due to a decreased drug activation or drug inactivation. 
This phenomenon can occur, for example, due to Glutathione – S- Transferase (GST) 
superfamily, a group of detoxifying enzymes that protect cellular macromolecules from attack 
by reactive electrophiles. GST play an important role in the regulation of MAPK pathway via 
protein- protein interactions (122-124). Some studies show an increased expression of GST in 
cancer allowing the detoxification of the anticancer drugs, which culminates in less efficient 
cytotoxic damage of cells (122, 123, 125). Glutathione transferase levels were found to be 
Figure 1.7. Mechanisms of acquired resistance to cancer therapy. The main resistance 
mechanisms to cancer therapy involve changes in drug metabolism, like drug inactivation, 
mutation of drug target or target pathway, and drug efflux pumps that decreases the amount of 
drug that has an effect on cancer cells. The crosstalk between oncogenic pathways is also an 
important resistance mechanism. Some cancer cells are also able to increase DNA repair 
allowing mutated cells to survive. Tumor heterogeneity plays also a crucial role in therapy 
resistance: not all cells are sensitive to treatment, and resistant cells can proliferate and 
contribute to tumor growth. One of the main resistance mechanisms is dysregulated cell death 
control which leads to cancer cell survival, and consequently, to cell proliferation and tumor 
grow. 
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higher in melanoma cells compared to normal melanocytes, which allows cancer cells to protect 
themselves against oxidative stress (126, 127).  This increased expression of GST has also been 
associated with resistance to apoptosis (122, 123, 125).  
A drug’s efficacy is influenced by the drug target or mutations in the drug target pathway. Many 
anticancer drugs target topoisomerase II (example Etoposide) which is a nuclear enzyme 
essential for DNA replication, chromosome condensation and chromosome segregation. This 
enzyme forms a complex with DNA that is normally transient. When a topoisomerase II 
inhibitor is present, the complex stabilizes leading to DNA damaged and later results in cell 
death. Some cancer cells acquire mutations in topoisomerase II gene, conferring resistance to 
this type of anticancer drugs (122, 128, 129). A study shows that melanoma cells exposed to 
etoposide (which induces DNA damage) have tenfold reduced topoisomerase II activity 
corresponding to an increased drug resistance (126, 130, 131). Another example is the mutation 
of cellular receptors such as Epidermal Growth Factor Receptor (EGFR) or in one of its 
downstream targets (122, 128, 129). 
The efficacy of a drug depends also in the real amount of drug able to reach the tumor. One of 
the most resistance mechanisms studied is the drug efflux that results in a reduced drug 
accumulation. Several cell membrane transport proteins, such as the ATP – Binding Cassette 
(ABC) proteins have been associated with drug resistance by promoting drug efflux (121, 122). 
The ABC superfamily proteins function as ATP-dependent efflux transports, mediating drug 
efflux resulting in lower drug accumulation (126, 132). P- glycoprotein (Pgp) and multidrug 
resistance protein (MRP) belongs to ABC transports superfamily and are thought to contribute 
to treatment failure (133). Melanoma cells express MRP, yet a study shows that its expression 
did not increase after chemotherapy (134). 
The response to anticancer drugs culminates direct or indirectly in DNA damage, leading to 
cell death. An increased repair of drug-induced DNA damage is an important mechanism of 
chemo-resistance. The DNA damage response can occur through the nucleotide excision repair 
(NER), or homologous recombination (HR). This mechanism can reverse the effect induced by 
anticancer drugs, such as cisplatin, that causes DNA crosslinks leading to apoptosis.  There are 
some studies showing that some drug resistant melanoma cell lines present an increased NER 
of DNA damage (126, 135). Furthermore, DNA-mismatch repair (MMR) deficiency results in 
drug-resistance by changing the ability of cancer cells to repair DNA damage (136). 
The crosstalk between signaling pathways in cancer is also a mechanism that can contribute to 
drug resistance (137). Connections between signaling pathways give the cell the ability to deal 
with perturbations of homeostasis. In this way, cancer cells are able to activate a similar 
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mechanism through the activation of an alternative pathway which will compensate the drug 
effect on one pathway. It has been shown that the crosstalk between MAPK and PI3K/AKT 
signaling pathways contributes to resistance in melanoma (137, 138). RAS is a small G protein 
located upstream of this two pathways. Upon MAPK inhibition, cancer cells display a strong 
PI3K activation leading to cell survival and melanoma progression (64, 138).  
The deregulation of the apoptotic pathway is probably one of the most important mechanisms 
of resistance in melanoma cells. Apoptosis, often called programmed cell death, involves two 
different pathways: an intrinsic and an extrinsic pathway. The extrinsic pathway is triggered by 
binding of Fas ligand to death receptors that belong to the Tumor Necrosis Factor (TNF) 
superfamily. These are extracellular membrane receptors, which activates caspase 8 an 
important component of the apoptotic pathway. Caspases are enzymes that cleave after aspartic 
acid and become activated upon cleavage by other caspases (proteolytic cascade). The intrinsic 
pathway can be triggered by different stimuli, including death receptor signaling and 
intracellular signals like the absence of growth factor, hormones or cytokines (negative stimuli) 
and radiation, toxins, hypoxia and free radicals (positive stimuli). Once activated, the intrinsic 
pathway leads to the release of mitochondrial cytochrome-c, which in combination with Apaf-
1 results in caspase 9 activation. The intrinsic pathway is mainly controlled by Bcl2 proteins, 
which include proteins with pro- and anti- apoptotic activity. The two pathways converge with 
the activation of caspase 3 and 7 that cleave proteins responsible for nuclear membrane and 
cytoskeletal structure, replication systems and DNA repair (126, 139). Dysregulated cell death 
control can be associated with three main molecular changes: enhanced survival signals, 
activation of anti-apoptotic factors and inactivation of pro-apoptotic effectors(21, 126, 140). 
Tumor heterogeneity also plays a crucial role in anticancer drug resistance. Tumor 
heterogeneity can be defined as the differences between tumors of the same type in different 
patients and between cancer cells within the same tumor mass (141, 142).  Resistance can 
develop from a clone with a specific characteristic that allows it to survive to a certain drug, 
that proliferates originating a resistant cell subpopulation. Recent studies have demonstrated 
that a fraction of cells that compose part of the heterogeneous tumor mass have stem cell 
properties and are usually drug resistance. The cancer treatment affects the sensitive cells, but 
not the resistant cells that survive and can expand contributing to the disease relapse (122, 141).  
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1.2.5 The Role of TRIB2 in resistance to anti-melanoma drugs 
 
Recently, the Link lab has discovered a novel resistance mechanism to anti-cancer drugs 
currently in clinical trials, namely to BEZ235, a PI3K/mTOR inhibitor, BAY236 and 
BAY1082439, both PI3K inhibitors and Rapamycin, a mTOR inhibitor and also to conventional 
cytotoxic drugs DTIC, gemcitabine and 5-fluorouracil, mediated by Tribbles homolog 2 
(TRIB2) (143). TRIB2 is a protein that belongs to the Tribbles family of proteins, enhanced 
cell resistance to these drugs (143) . Furthermore, TRIB2 protein levels were correlated with 
AKT activation. TRIB2 was able to inhibit Forkhead BoxO (FOXO), a tumor suppressor gene, 
contributing to the malignant phenotype of melanoma cells. These findings suggest that TRIB2 
is conferring resistance by reducing cell death induced by PI3K/mTOR inhibitors (143, 144). 
In fact, previous studies from this group proved that TRIB2 is overexpressed in melanoma cell 
lines and in melanoma patients. TRIB2 expression correlates with disease stage and clinical 
progression, suggestingTRIB2 as a potential biomarker for diagnosis and prognosis of 
melanoma (14, 144).  
The Link lab found that TRIB2 is a repressor of FOXO through a screening for FOXO 
repressors (144). FOXO suppresses cell survival and proliferation through regulation of the 
expression of apoptotic proteins and cell cycle regulators. Some studies have shown that 
hyperactivation of MAPK pathway leads to FOXO inactivation (37, 145). Since FOXO 
functions as a tumor suppressor gene inactivated in many human cancers inhibiting its repressor 
proteins might represent an attractive therapeutic strategy to reactivate them. ERK and p38 are 
known to phosphorylate FOXO1 at various sites, suggesting that MAPK signaling cascade may 
play a key role in FOXO regulation (37, 119, 146). FOXO regulation is receiving increasing 
attention in cancer research since FOXO family members were found to be associated with 
cancer initiation, progression and resistance (36). FOXO proteins represent a subfamily of 
transcription factors that belong to the forkhead family (145, 147). In mammals there are 4 
FOXO genes: FOXO1, FOXO3, FOXO4, and FOXO6 involved in crucial cellular processes like 
regulation of stress resistance, metabolism, cell cycle arrest and apoptosis (146-148). FOXOs 
activity is regulated at three different levels: subcellular localization, stability and 
transcriptional activity (144). This regulation is mediated by different processes such as 
phosphorylation, acetylation and ubiquitination FOXO proteins regulate biological processes 
involved in cell proliferation, cell cycle progression, cell differentiation, tissue homeostasis, 
angiogenesis and apoptosis through apoptotic genes such as cyclin-dependent kinase inhibitor 
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p27, BIM, Fas ligand and Bcl-6 (36, 37, 146, 147, 149). As result, it is not surprising that 
deregulation of FOXO proteins may be involved in some pathological processes such as cancer.  
It was shown that the activation of PI3K or MAPK pathways leads to the repression of FOXO-
mediated growth arrest and apoptosis (37). FOXO transcription factors are tumor suppressors 
that are inactivated in some human cancers (36, 150). It was shown that FOXO overexpression 
inhibits tumor growth in vitro and tumor size in vitro in breast cancer, correlating FOXO 
cytoplasmic localization of FOXO with a poor prognosis. Contrarily, when FOXO has a nuclear 
localization cell cycle stops, angiogenesis is reduced and apoptosis is induced, contributing to 
tumor regression. The tumor suppressor role of FOXO was also described in leukemia, prostate 
cancer, and glioblastoma (150-154). Most importantly, recent studies, have revealed that the 
cytostatic and cytotoxic effects of many chemotherapeutic agents, including paclitaxel, 
doxorubicin, lapatinib, gefitinib, imatinib, cisplatin and tamoxifen are mediated by FOXO 
activity (36). Therefore, FOXO can be determinant to the sensitivity to chemotherapeutic drugs. 
It has been established that AKT phosphorylates FOXO proteins, promoting cell survival, since 
FOXO regulates pro-apoptotic proteins including TRAIL and BIM. FOXO phosphorylation by 
AKT induces its translocation to cell cytoplasm and posterior degradation, in particular 
FOXO3a, which is also regulated by MAPK pathway. FOXO can be inactivated, also by the 
crosstalk between PI3K and MAPK pathways (36, 155). Thus, FOXO is considered a very 
important target to melanoma treatment. An interesting approach would be the reactivation of 
FOXO to take advantage of its tumor suppressor properties. Importantly Zanella F. et al., 
discovered, TRIB2 as a novel FOXO-repressor, that might be useful as a target to reactivate 
FOXO factors(144).  
 
 
Tribbles 
TRIB2 belongs to the tribble family of genes, first described in 2000 as a Drosophila protein 
that coordinates morphogenesis by inhibiting mitosis. Tribble family members were identified 
in a genetic screen that aimed at identifying mutations that control cell division and cell 
migration during embryonic Drosophila development. The name originates from the fictional 
small animal that vexed the crew of the Enterprise in the “Trouble with Tribbles” episode from 
Star Trek television series (156, 157). Tribbles encodes an evolutionarily conserved protein 
family that influences cell proliferation, motility and metabolism (158). Tribbles homologs are 
characterized by the presence of a N-terminal portion, a central serine/threonine kinase like 
domain and a C-terminal that contains a COP-1 binding site for E3 ubiquitin ligases and a 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
22 
 
MEK1 binding site which mediates interactions with multiple Mitogen-activated protein kinase 
kinases (MAPKKs) (figure 1.8). These proteins are considered catalytically inactive since they 
lack conserved residues from the characteristic ATP binding site. Thus, are considered 
pseudokinases (156-159). However, recent data shows that human TRIB2 has the ability to bind 
and hydrolyze ATP showing a weak kinase activity(160-162).   
 
 
 
 
 
 
 
 
 
The mechanism of action of Tribble proteins is still not fully understood, though some 
investigators hypothesized that Tribble proteins function as scaffold proteins that contributes to 
balance signaling pathways, and in several contexts they facilitate ubiquitin-dependent 
degradation of their target protein (156, 163). There are three mammalian Tribble homologs 
proteins: TRIB1, TRIB2 and TRIB3. Its structure includes a pseudokinase domain, a MEK1 
and a COP-1 binding site in the C-terminal (158, 161). TRIB1 is highly expressed in the bone 
marrow, peripheral blood leukocytes, thyroid gland and pancreas (158, 164). TRIB2 is highly 
expressed in peripheral blood leukocytes, thymus, heart, brain, kidney, lung, skin and white 
adipose tissue while TRIB3 is more expressed in human liver (158, 164). Tribbles family 
members coordinate a number of critical cellular processes including glucose and lipid 
metabolism, inflammation, cellular stress, survival, apoptosis and tumorigenesis (158). Tribble 
s proteins regulate AKT and MAPK signaling pathways via regulating the activity of MAPK 
and PI3K pathways. TRIB2 was described as a dosage dependent suppressor of FOXO, mainly 
as modulator of cytoplasmic location of FOXO3a (157, 161). Aberrant regulation of 
pseudokinases has been implicated in the progression of cancer (157). Recent studies have 
shown that Tribble pseudokinases play an important role dysregulating signaling in malignant 
hematopoiesis. In fact, TRIB1 and TRIB2 appear to function as oncogenes in acute 
myelogenous leukemia (AML) (164-166). TRIB1 and TRIB2 induce efficient degradation of 
one of the members of CCAAT/ enhancer binding proteins (C/EBPs), C/EBP α. C/EBPs are 
Figure 1.8. Structure of the Tribble protein family. Tribble proteins have 3 main domains: 
a central serine/ threonine pseudokinase domain, MEK1 binding domains, which mediates 
interaction with MAPK and COP-1 binding site. 
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transcription factors that regulate several processes like cell cycle, inflammation, metabolism, 
differentiation a proliferation. The C/EBP α function is better characterized in the hematopoietic 
system: controls maturation of myeloid lineage (167, 168). The C/EBP α has two main 
isoforms: p42 that function as a tumor suppressor gene and p30, an N–terminally truncated 
form that function as an oncogene. TRIB2 is highly expressed in patients with AML. It was 
shown that TRIB2 leads to the degradation of C/EBP α p42 via E3 ligase COP1 domain, leaving 
p30 isoform intact, which leads to uncontrolled proliferation.  
In vitro and in vivo data shows that TRIB2 transcript levels are elevated in melanoma cell lines 
and in patients with malignant melanoma (144). These high levels TRIB2 were shown to 
facilitate the growth and survival of melanomas by downregulation of FOXO activity (14). 
Published work from the Link laboratory has shown that TRIB2 knockdown increases the 
activity of FOXO in melanoma and reverts the malignant phenotype of malignant melanoma 
cells where TRIB2 is overexpressed (144). More recently, Hill et al., showed that TRIB2 could 
be used as a biomarker for diagnosis and progression of melanoma (14, 144). A biomarker can 
be defined as a biological characteristic that can be objectively measured and evaluated as an 
indicator of a determined process or disease. In these way, a biomarker is a powerful tool that 
provides information about the disease progression (169, 170). In oncology, a biomarker 
provides information about differential diagnosis, prognosis, prediction of response to the 
treatment and they are essential to monitor disease progression. Biomarkers can be classified 
as predictive, prognostic or diagnostic biomarkers. A predictive biomarker helps to predict a 
response to a specific treatment regarding a specific characteristic such as the presence/absence 
of a protein. A prognostic biomarker gives information about the disease progression, 
recurrence or death independently of the treatment received. A diagnostic biomarker is used in 
order to detect/ confirm the presence of a specific disease or a specific condition that allows the 
classification of a subtype of disease (170-172). Hill et al., found that TRIB2 expression 
correlated with disease stage and prognosis. They demonstrated, with a statistical significant 
transcription difference, that TRIB2 expression was elevated in metastatic melanoma samples 
compared to normal skin (14). This group also proved that TRIB2 protein levels correlates with 
AKT activation: TRIB2 interacts with AKT activating it via COP-1 domain. Through this 
experiments they were able to show that TRIB2 confers resistance to inhibitors such as PI3K 
inhibitors (BAY236 and BAY1082439) , mTOR (a serine/threonine kinase that belongs to PI3K 
pathway) inhibitors (Rapamycin), PI3K/MTOR inhibitors (BEZ235) and also to conventional 
cytotoxic drugs (DTIC, gemcitabine and 5-fluorouracil) (143).  In this study, they created stable 
isogenic TRIB2 cell lines and submitted them to BEZ235, a PI3K/mTOR inhibitor. Through 
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the analysis of SubG1 cell population and reduced caspase 3 activation, they proved that the 
high levels of TRIB2 correlated with cell resistance to this drug (143). The same happened 
when cell lines were treated with BAY236 and BAY439, both PI3K inhibitors: TRIB2 reduced 
cell death induced by these drugs. When exposed to Rapamycin, an mTOR inhibitor, the 
isogenic cell lines with higher levels of TRIB2 displayed resistance to this compound (143). A 
deeper investigation demonstrated that cell lines with higher TRIB2 protein levels correlated 
with AKT activation through its phosphorylation on serine 473 and also with increased total 
AKT. In melanoma cells with TRIB2 depletion the levels of AKT pSer473 and total AKT were 
lower (143). Surprisingly, TRIB2 overexpression contributed to increased levels of AKT 
pSer473 and total AKT before and after the treatment with PI3K and mTOR inhibitors which 
suggests that drugs targeting PI3K and mTOR may not be clinically efficient in tumors where 
TRIB2 is overexpressed, like in melanoma. Moreover, they proved that TRIB2- mediated 
resistance was AKT-dependent via FOXO3a (143). AKT1 phosphorylates FOXO3a (tumor 
suppressor gene) for proteasome degradation, and also activates E3 ubiquitin ligase mouse 
double minute 2 homologue (MDM2) with consequent apoptosis inhibition mediated by p53. 
MDM2 is considered and oncogene once it regulates p53 activity (173). MDM2 function as a 
E3 ligase that ubiquitinates p53 for degradation blocking its transcriptional activity directly 
(174-176). The authors showed that TRIB2 and AKT interacts and form a complex, promoting 
AKT activation and consequent inhibition of P53 mediated apoptosis. Concomitant to reduced 
p53 protein levels, they also found that P53 target genes were downregulated, including: p21, 
MDM2, Bax and Puma. TRIB2 COP1 binding site was shown to be essential for AKT 
activation. In this way, through several experiments, our group showed that TRIB2 is able to 
activate AKT leading to P53 and FOXO3a inactivation and confers resistance to PI3K inhibitors 
(143). In vivo experiments confirmed that TRIB2 confers resistance to PI3K inhibitors. The 
authors created isogenic 293T subcutaneous tumors in the flanks of NOD/Scid mice. Tumor 
growth revealed to be independent of TRIB2 status. When treated daily with BEZ235, a 
PI3K/mTOR inhibitor, the 293T-GFP xenograft tumors reduced significantly while 293T-
TRIB2 tumors were highly resistant to treatment showing that the high levels of TRIB2 reduced 
the efficacy of BEZ235 in vivo (143). To compare to a clinical situation, they analyzed tumor 
tissue samples from melanoma, pancreatic and colon cancer were analyzed, they found that the 
levels of TRIB2 transcription and proteins were elevated in tumor tissues compared to the 
normal tissue samples. Similar to in vitro models, they proved that in tumor samples the levels 
of TRIB2 the levels of AKT pSer473 and pSer253-FOXO3a protein levels were significantly 
higher, confirming their experiments. Also, they demonstrated that the transcripts and proteins 
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of FOXO dependent gene such as BIM, FasLG and TRAIL were significantly lower in 
melanoma samples compared to the normal control tissue samples (143). In summary, Hill et 
al., discovered a new mechanism: TRIB2 binds to AKT via COP1 domain promoting the 
activation of AKT via Ser473 phosphorylation, which in turn phosphorylated MDM2, 
increasing its activity inhibiting p53 mediated apoptosis (figure 1.9). AKT also leads to 
FOXO3a phosphorylation via Ser235 sending it to degradation. This study was extremely 
important once it revealed a novel resistance mechanism of TRIB2 mediated resistance to PI3K 
inhibitors, meaning that patients with TRIB2 overexpression are predicted to respond poorly to 
these treatments, rendering TRIB2 as a biomarker predicting the treatment outcome (143). 
Taking into account that:  (a) TRIB2 has a MEK1 binding site (figure 1.8) (157, 158, 177); (b) 
TRIB2 is highly expressed in melanoma cell lines and  in patients with melanoma (144) and (c) 
TRIB2 confers resistance to PI3K and mTOR inhibitors (143) we hypothesize  that TRIB2  
might also be conferring resistance to MEK inhibition as well, through a similar or unrelated 
mechanism. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Proposed model of TRIB2 mediated drug-resistance. In the left, with low levels 
of TRIB2 pathway is inhibited leading to apoptosis and tumor regression and consequently a 
good clinical response. In the right, with high levels of TRIB2, TRIB2 binds to AKT via COP1 
domain causing its activation via p-Ser473AKT. Activated AKT causes MDM2 
phosphorylation via Ser166 which and turn phosphorylates P53 sending it to degradation. AKT 
also phosphorylates FOXO3a via Ser235 sending it also to degradation, culminating with cell 
survival, tumor growth and finally, treatment failure. Adapted from Hill et all, Nat Comm, 
2017(143). 
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2. Methods 
 
2.1 Cell culture 
Cell culture is one of the most important tools used in molecular biology, providing systems to 
study the majority of diseases. The cell lines used are described in section 2.2. The cells were 
cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM) with Ultraglutamine 1 and 4,5g/L 
Glucose (Lonza, Verviers, Belgium) supplemented with 10% Fetal Bovine Serum (FBS) 
(Biowest, South America) and 5ml of Penicilin / Streptamicin (Amresco, Ohio). All cell lines 
were routinely cultured in 100mm plates (SLP life science, Korea) or 60mm plates (SLP life 
science, Korea) and maintained in an incubator (Thermo electron corporation 311, Canada) at 
37ºC and 5% carbon dioxide (CO2). Culture medium was changed every 2 or 3 days. When 
cells reached 70-80% confluency, cells were washed twice with 1X Phosphate Bovine Serum 
(PBS) (Sigma Aldrich, USA) and coated with 1.5X Trypsin (Sigma Aldrich, USA), diluted in 
PBS. Trypsin is used to detach cells from the plates and maintain a subculture. 
For long term storage, we trypsinized and centrifuged cells (VWR 881117, Taiwan) at 1100 
revolutions per minute (rpm) for 4 minutes, we removed the supernatant and ressuspended the 
cells in fresh media supplemented with 10% FBS and 10% Dimethyl-sulfoxide (DMSO) 
(VWR, France) that functions as a cryopreserving agent. Cells were stored in cryovials (VWR, 
China) at -80ºC and then, transferred to -150ºC. 
For thawing, we placed the cryovials for a couple of seconds at 37ºC water bath (Clifton, Great 
Britain) and the solution transferred to 15ml falcon tubes (Labbox, Spain), and then centrifuged 
at 1100 rpm for 4minutes. We discarded the supernatant, containing DMSO in order to avoid 
cell damage, and cells were ressuspended in 1ml media and plated in 100mm plates. 
We performed cell counting using a Neubauer chamber (Blau brand, Germany). Briefly, we 
collected 10µL of cell suspension and mixed with 10µL Trypan Blue (Sigma Aldrich, UK) in 
an Eppendorf tube (Eppendorf, Germany). We transferred 10µl to the Neubauer chamber and 
the four external corners were counted. Cell concentration was obtained according to this 
equation: (X1+ X2 + X3+ X4)/4 x 2 x 10
4 cells /mL (figure 2.1). 
All the procedures were performed under sterile conditions using a laminar flow chamber 
(Microflow, advanced biosafety cabinet class II, UK). 
 
 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
27 
 
 
 
 
 
 
 
 
 
 
 
2.2 Cell lines characterization 
For our study we used the following melanoma cell lines: G361, SK-Mel-28 and A375 and the 
non-melanoma cell lines: U2OS (osteosarcoma) and Human Embryonic Kidney (HEK) 293T 
cells. All of them provided by American Type Culture Collection (ATCC). Melanoma cell lines 
are characterized in table 2.1 
 
 
  
 BRAF NRAS P53 
G361 Wt* / Mutant Wt Wt 
SK-Mel-28 Mutant Wt R273H 
A375 Mutant ND** ND 
Table 2.1. Genetic characterization of the melanoma cell lines used. 
X1 X2 
X3 X4 
Figure 2.1. Scheme of a Neubauer Chamber. The total number of cells results from the 
average number of cells from the four external corners, X1, X2, X3 and X4 multiplied by the 
factor of dilution (in our case 2) and by 104: (X1+ X2 + X3+ X4)/4 x 2 x 10
4 cells /mL. Adapted 
from Ansair N. et al, Methods Cell Biol, 2013. 
*Wt – Wild Type; **ND – non-descriminated 
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 Since Tribbles family members are highly conserved and might be functionally redundant, we 
decided to analyze the mRNA and protein levels of all three proteins. We evaluated mRNA and 
protein levels using quantitative polymerase chain reaction (q-PCR) and Western Blot (WB) 
techniques, respectively. 
 
2.3 q-PCR 
The q-PCR is a sensitive method that allows the detection and quantification of minute amounts 
of nucleic acids. First, RNA is transcribed into a complementary DNA (cDNA) by reverse 
transcriptase from mRNA. Then, cDNA is used as a template for the qPCR reaction. The 
reaction is detected by the use of fluorescent reporters that permits the detection after 
hybridization of the probe with its complementary sequence, allowing to follow the procedure 
at the time that it happens and the quantification of the product accumulation (178). 
RNA extraction 
In order to perform the RNA extraction, we used E.Z.N.A.® Total RNA Kit (Omega) protocol, 
describe in annex A, from cell pellets collected from each cell line.  
CDNA synthesis 
For the cDNA synthesis we used NZY first-strand cDNA synthesis kit (Nzytech, Lisbon) 
thermal cycler (TC-48, BioRad) protocol in Annex B. The resulting cDNA was divided, one 
part was diluted 1:10 to the PCR and the remaining was frozen at –80ºC.  
PCR 
PCR is composed of 3 different steps: Denaturation in which the high temperature allows the 
separation of the DNA into 2 single strands; Annealing when the temperature is lowered 
allowing the primers to attach to the DNA strand; the final step is the Extension in which the 
temperature is raised again and a new complementary strand of DNA is formed by Taq 
polymerase (179). For qPCR we used LuminoCt Syber Green qPCR ReadyMix L6544 (Sigma 
Aldrich, USA). The protocol included 20 seconds at 94ºC plus 3 seconds at 94ºC for 
denaturation, 20 seconds at 56ºC for annealing/extension and then at 4ºC. We performed three 
technical replicates. The primers used are described in table 2.2. Results were analyzed using 
Bio-Rad CFX Manager 3.1 software. 
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2.4 Western Blot 
The protein levels were assessed using the WB technique, commonly used to separate and 
identify proteins. Briefly, the proteins are separated according to their molecular weight in a 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  The percentage of 
SDS gel should be according to the size of the proteins of interest. The separated proteins are 
then transferred to a nitrocellulose membrane. Next, the membrane is blocked, usually in 5% 
milk diluted in 1X tris-buffered saline tween (TBS-T), to prevent the antibodies from binding 
to the membrane nonspecifically. After blocking, the proteins of interest are detected using 
specific primary antibodies and the revelation solution (180). 
Once the cell plates (60mm) were confluent, we performed two washes with 1X PBS and 
trypsinized the cells. Next, we centrifuged cells at 1100 rpm for 4m and discarded the 
supernatant. We ressuspended the cell pellet in 1X PBS and centrifuged for brief seconds. We 
removed the supernatant and froze the cell pellet at -20ºC. 
 
Protein Extraction 
The protein extraction is the first step of WB. Protein extraction was performed in ice, using 
RIPA buffer (0,1% sodium dodecyl sulfate (SDS) (Applichem, Germany), 0,5 % Sodium 
deoxycholate (DOC) (Sigma Aldrich, New Zeeland), 1% Nonidet P (NP) 40 (Sigma Aldrich, 
USA), 50mM Tris Hydrochloric acid (HCl) pH 8(Sigma Aldrich, USA), 150 mM NaCl (Merck, 
Germany), 0,05M NaF (VWR, EC), 1 mM sodium orthovanadate (OVO4) (Sigma Aldrich, 
Gene Oligo Name Sequence Supplier 
TRIB1 hTRIB1_RTPCR_FOR_I ATCGCCGACTACCTGCTG NZYTech 
hTRIB1_RTPCR_REV_I GTAATGTTGCTGTGCGATGG NZYTech 
TRIB2 hTRIB2_RTPCR_FOR_I GACTCCGAACTTGTCGCATT NZYTech 
hTRIB2_RTPCR_REV_I ATGAGCAGACAGGCAAAAGC NZYTech 
TRIB3 hTRIB3_RTPCR_FOR_I TGCCCTACAGGCACTGAGTA NZYTech 
hTRIB3_RTPCR_REV_I GTCCGAGTGAAAAAGGCGTA NZYTech 
GAPDH GAPDH FOR RT-PCR CAATGACCCCTTCATTGACC NZYTech 
GAPDH REV RT-PCR TTGATTTTGGAGGGATCTCG NZYTech 
Table 2.2. Primers used in q-PCR. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
30 
 
USA), 0,0001µg/µL Calyculin (Santa Cruz, Dallas), 0,01 0,0001µg/µL Protease Inhibitors 
Cocktail (PIC) (Sigma Aldrich, USA)) that effectively lyses and extracts membrane, 
cytoplasmic and nuclear proteins while avoiding protein degradation. We add the proper 
amount of RIPA to the cell pellet and homogenized the samples by repetitive pipetting followed 
by a 20-minute incubation on an orbital shaker (Labnet, New Jersey) at 4ºC. Next, we 
centrifuged the samples at 15000 rpm (VWR, Japan) for 20 minutes at 4ºC. Once centrifuged, 
we transferred the supernatant (protein fraction) to a new Eppendorf tube.  
 
Protein Quantification 
Next, we normalized all samples to the same final protein concentration using the Bradford 
(NZTech, Portugal) assay accomplished by measurement of absorbance at 590 nm. It is a 
colorimetric protein assay based on an absorbance shift of Comassie Brilliant Blue, being a 
rapid and sensitive method. This method relies in the fact that the concentration of an unknown 
sample is based on a protein standard/ reference with similar properties to the sample being 
analyzed, like Bovine Serum Albumin (BSA) 2mg/mL (ThermoFisher Scientific, USA) with 
serial dilutions (181, 182). The Bradford assay involves the binding of Comassie Blue dye to 
proteins. This dye can present three different colors: cationic (red), neutral (green) and anionic 
(blue). In the presence of proteins, the dye is converted to a stable blue form, detected at 595nm 
using a microplate reader. For calculation of protein concentration, we used a linear standard 
curve, obtained from BSA solutions with different concentrations: 0µg/mL, 150 µg/mL, 300 
µg/mL, 600µg/mL 800 µg/mL,1000 µg/mL and 2000 µg/mL. We diluted our samples with 10 
of dilution factor. From this dilution, we loaded 5µL to a microplate (in duplicated) and added 
250µL of Bradford to each well. The absorbance was measured on a microplate reader (Tecan 
Life Sciences, Austria) using I-control software. Using the absorbance and our linear standard 
curve ("y = mx + b" where y = absorbance at 595 nm and x = protein concentration) we 
calculated our protein concentration and calibrated our samples at the same concentration. Our 
laemli 6x stock solution contains 0,2M TrisHCl (Sigma Aldrich, USA) pH6.8, 40% of glycerol 
(Sigma Aldrich, USA), 0,04% Blue Bromophenol (Santa Cruz, Dallas), 0,3 M of SDS 
(Applichem, Germany) and 20% of β-Mercaptoethanol (Sigma Aldrich, Steinheim). Laemmli 
buffer allows to see the sample during loading and the run (blue bromophenol), increases the 
density of the sample (glycerol). The SDS present in laemmli buffer denatures proteins and 
gives negative charge so they can be separated by size. The β-Mercaptoethanol reduces 
disulfide bonds. We heated the samples at 95º in a sample mixer/ heater (thermo shaker, EU) 
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for 5 minutes. This step will allow denaturation of the proteins and migration through an electric 
field. Samples were immediately loaded on a gel or kept at -20º C for long-term storage.  
 
SDS-PAGE 
Proteins were separated according to their molecular weight on a 10% SDS-PAGE gel (0,4M 
Tris (Sigma Aldrich, USA) pH 8.8, 10% acrylamide (Fisher BioReagents, USA), 0,1% SDS 
(Applichem, Germany), 0,1% Ammonium Persulfate (APS) (Sigma Aldrich, USA), 0,15% 
Tetramethylethylenediamine (TEMED) (Santa Cruz Biotechnologies, Dallas). The stacking gel 
was prepared with 0,1 M Tris (Sigma Aldrich, USA) pH 6.5, 3,8% acrylamide, 0.08% SDS 
0,1% APS, 0,1% TEMED. The electrophoresis was performed in SDS-Page running buffer 
(0,02M Tris (Sigma Aldrich, USA), 0,025M Glycine (Sigma Aldrich, Belgium), and 
0,003MSDS (Applichem, Germany)) using the BIO-RAD WB power source initially at 75V 
until proteins reach the running gel and then at 140V. 
 
Protein Transference and detection 
We performed a wet transfer on a nitrocellulose membrane (Amersham, UK). The SDS-PAGE 
Transfer Buffer used contained 20% methanol (VWR, France), 0,05M TRIS (Sigma Aldrich, 
USA) and 0,05M Glycine (Sigma Aldrich, Belgium)). Following, we blocked the membrane in 
5% milk (Nestlé, Portugal) for one hour, and incubated with the primary antibody (see 
antibodies and dilutions in annex C) overnight at 4ºC using an roller mixer (Stuart, UK) (see 
primary antibodies references in annex C). Next day, the membranes were washed three times 
for five minutes with TBS-Tween (0,075M Tris (Sigma Aldrich, USA), 0,15M NaCl (Merck 
Millipore, Germany) and 0.1% Tween 20 (Merck Millipore, EC) followed by one-hour 
incubation at room temperature with the proper secondary antibody (see annex C). All 
membranes were washed three times for five 5 minutes. Later, all membranes were incubated 
for 5 minutes in a home-made enhanced chemiluminescente (ECL) (1,25mM Luminol (Sigma 
Aldrich, USA) diluted in DMSO, 0,2 mM p-coumaric acid (Sigma Aldrich, UK) diluted in 
DMSO, 0,1M TRIS pH 8,5, 0,01% H2O2 (VWR, EC) and signal was developed using the 
Chemidoc (BioRad, USA). Briefly, in the presence of horseradish peroxidase (HRP), coupled 
to the antibodies, and peroxide, luminol oxidizes producing an excited state product that emits 
light. Light emission signal was captured using ImageLab (Bio-Rad) software. 
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2.5 Cell lines generation 
In order to test our hypothesis, that TRIB2 confers resistance to MEK inhibition, and taking 
into account the protein expression of the three Tribbles in melanoma cell lines, we generated 
TRIB2 knockdown using shRNA, and TRIB2 knockout (KO) using Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR). This dual approach allows us to have, on 
one hand a system with lower expression of TRIB2 and on the other hand a system where we 
abrogated TRIB2 expression (figure 2.2). With these tools we will be able to evaluate the effect 
of TRIB2 expression after MEK inhibition. At the same time, we also generated TRIB2-FLAG 
knock-in (KI) for future experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.1 shTRIB2 
Interference RNA (RNAi) is a powerful tool to study gene function through gene silencing. The 
silence mechanisms can lead to the degradation of the target mRNA and can be induced by 
double stranded siRNA or vector based short hairpin RNA (shRNA). We used shRNA against 
TRIB2 (see the construct maps on Annex D). The mechanism for protein knockdown consists 
in the introduction of a bacterial vector encoding for a shRNA of interest. The vector is 
incorporated in cell nucleus and shRNA is synthetized in the nucleus of transfected cells. The 
shRNA, an oligonucleotide sequence that contains a loop structure, is processed to small 
Figure 2.2. Different cell systems to test if TRIB2 confers resistance to MEK inhibition. 
We created a system with lower expression of TRIB2 using a short hairpin technique and a 
system in which we abrogated TRIB2 expression using the CRISPR-Cas9 technique. In this 
way, we originated 2 different systems to test our hypothesis that TRIB2 confers resistance 
to MEK inhibition. 
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interference RNA (siRNA) by DICER (ribonuclease III enzyme). The siRNA is then loaded 
onto the RISC complex where the process of target mRNA recognition and degradation takes 
course (183, 184). The siRNA binds to the target mRNA in a sequence specific manner leading 
to its cleavage (183, 184). These tools have been previously generated and validated in our lab. 
We plated the cells the day before transfection. Next day, we changed the media before and 
transfected 2µg of the plasmid coding for the shGFP (technical control) and the shTRIB2 (see 
Annex D) using lipofectamin 2000 (Thermo Scientific, Scotland). The day after we replace the 
plates with fresh media, and 48 hours after transfection we added puromycin (Amresco, Ohio) 
selection.  
 
2.5.2 TRIB2 KO – CRISPR 
For TRIB2 abrogation we used CRISPR-Cas9 technique. CRISPR-CasCas9 allows genome 
editing being considered highly specific and efficient. This technique is based on a small guide 
RNA that defines the target location and the Cas9, a nuclease that induces double strand breaks 
(dsbreaks) at specific genome loci. Protospacer adjacent motif (PAM) is a 2-6bp immediately 
adjacent to DNA sequence targeted by Cas9, which is crucial for the Cas9 to recognize, bind 
and cleave the target (185). Using this method small non sense mutations are introduced into 
the reading frame of a target gene via NHEJ a repair mechanism that joins the 2 broken ends 
together leading to insertions/ deletions. The CRISPR-Cas9 machinery can be introduced into 
cells through lentivirus or DNA vector transfection (186). 
The CRISPR-CasCas9 system targeting TRIB2 was previously designed and validated in our 
laboratory. Similar to what previously described, we plated the cells the day before transfection 
in 6-well plates. We transfected 2µg of the plasmid coding for guide RNA and Cas9 (px459, 
addgene, pSpCas9(BB)-2A-Puro (PX459)). We changed the media the following day and added 
puromycin two days after for 48h to select the cells that contained the plasmid. In order to get 
individual clones, we trypsinized the cells and performed 4-5 serial dilutions to allow single 
clones to grow individually. The different clones are selected by washing the cells twice with 
1X PBS and individually trypsinized and plated them in a 24 well plate. When confluent, we 
trypsinized the cells and plated them in two 60mm plates, one plate was used to extract protein 
and test by WB and the second plate was used to keep a frozen stock. 
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2.5.3 TRIB2-FLAG KI – CRISPR 
If our hypothesis of TRIB2 overexpression being responsible for conferring resistance to MEK 
inhibitors is confirmed, we will proceed to characterize underlying the mechanism through the 
analysis of protein-protein interaction and protein-localization assays. To this end, we 
simultaneously generated a TRIB2-FLAG Knock-In (KI) also using the CRISPR-Cas9 system. 
The CRISPR-Cas9 system can be used to generate a knock-In, an insertion of exogenous DNA 
sequence to a specific locus in mammalian cells. This occurs when dsbreaks induced by 
CRISPR-Cas9 are repaired by homology directed repair (HDR) in the presence of a specific 
template (187). FLAG is a tag. A tag is composed of a small DNA sequence, which is fused 
with the protein of interest using DNA recombinant technology. The specific tag, along with 
the respective antibody, allows protein detection in a very specific and sensitive manner. Tags 
are also used for protein purification and identification of protein-protein interactions (188, 
189).  
 
The protocol was similar to the one described in TRIB2 KO -CRISPR (section 2.5.2), with the 
difference that during the transfection we added an oligo (NZY Tech, sequence: CTC GCC 
AGC GAC TCA TCT CTC CAG CGG GTT TTT TTT) that is used as a template for HDR. 
Clones were validated by WB. 
 
 
 
2.6 Experimental Conditions Optimization  
2.6.1 Drug concentration and time-points 
To confirm that our drug, Refametinib (Bay 86-9766, or as in several figures referred to as 
BAY766; MEK inhibitor, kindly provided by Bayer AG, Germany), induced cell death and in 
which concentrations and time-points it was mostly effective, we performed a pilot experiment. 
In this experiment we tested two different drug concentrations, 100nM and 1µM and six 
different time-points: 4, 8, 12, 24, 48 and 72 hours, based on previous studies (143, 144). We 
plated the cells the day before and added the drug after changing the media. Cells were then 
trypsinized, centrifuged and ressuspended in fresh media.  
To confirm that Refametinib inhibits MAPK pathway we performed a Western Blot to evaluate 
the phosphorylation status of a downstream effector of MEK, ERK using a phosphor specific 
antibody against p-ERK (annex C). 
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Our main goal is to investigate if TRIB2 confers resistance to MEK inhibition. We analyzed 
cell death as a readout for resistance. In this way, was important to confirm that our MEK 
inhibitor, Refametinib (BAY766) induces cell death in our melanoma cell lines. 
Cell death was analyzed using Annexin V / Propidium Iodite Protocol. 
 
Annexin V / Propidium Iodite (PI) Protocol 
We performed Annexin V/PI protocol to analyze cell death after 72 hours treatment. Apoptosis 
is a cell death program. Annexin V / PI protocol is widely used to determine if cells are viable, 
apoptotic, or necrotic by analyzing the differences in the plasma membrane integrity and 
permeability (190).  
PI is a nuclear stain, and it is economic, stable and a good indicator of cell viability making it a 
better choice, compared to other nuclear stains. PI staining is dependent on plasma membrane 
integrity. Cells undergoing late apoptosis or necrosis have changes in plasma and nuclear 
membranes. In this way, PI enters in the cell, passes the disrupted nuclear membrane and 
intercalates with nucleic acids, and display a red fluorescence. (190-192).  
Annexins are a family of calcium-dependent phospholipid-binding proteins. Annexins bind to 
phosphatidylserine (PS) to identify apoptotic cells. In normal viable cells, PS is located on the 
cytoplasmic surface of the cell membrane. During apoptosis, PS is translocated from the inner 
to the outer of cell membrane. PS is exposed to the external cellular environment, making it 
accessible to annexin. Annexin V binds to PS and displays a highly fluorescent signal (191, 
193). Annexin V/PI protocol was done according to Annexin V/PI protocol sc- 4252 SK (Santa 
Cruz biotechnology), annex E. Etoposide (Sigma Aldrich, USA) was used as a positive control 
since it induces cell death. Results were obtained with Fluorescent Activated Cell Scanning 
(FACS) Calibur (BD Biosciences, Ireland) using CellQuestPro software and treated in 
GraphPad Prism6.  
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2.7 MEK inhibition Experiments 
In order to understand if TRIB2 was conferring resistance to MEK inhibitors we used the tools 
that he have generated: cell lines with TRIB2 KD and KO and added Refametinib, also known 
as BAY 86-9766, MEK inhibitor, to evaluate cell death as a readout for drug resistance. 
We plated the cells the day before, changed the media and add Refametinib at 100nM and 1µM 
for 72 hours and then analyzed cell death. The details of the experiments are described in table 
2.3 (Annex F). 
 
 
 
 
 A375 TRIB2 
knockdown 
G361 TRIB2 
Knockdown 
G361 TRIB2 
Knockout 
SK-Mel-28 
TRIB2 
Knockout 
Number of 
cells plated 
100000 200000 125000 125000 
Time of 
Treatment 
72hours 72hours 72hours 72hours 
Positive 
control for 
cell death 
Etoposide 50µM 
for 48h 
Etoposide 50µM 
for 48h 
Etoposide 
50µM for 48h 
Etoposide 
50µM for 48h 
Cell death 
analysis 
Trypan blue cell 
death counting 
Trypan blue cell 
death counting 
Trypan blue 
cell death 
counting 
Trypan blue 
cell death 
counting / 
Propidium 
Iodite 
Protocol 
 
The experiment with SK-Mel-28 KO (#8) cell line was performed twice. Results were analyzed 
using GraphPad Prism 6. Statistical analysis was performed using two-way Analysis of 
Variance (ANOVA) and Bonferroni’s correction test in GraphPad Prism 6. 
Table 2.3. Details of MEK inhibitor Refametinib (BAY766) experiments in different 
cell lines. 
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3. Results 
 
Tribbles are pseudokinases that play important roles in immune function, lipoprotein 
metabolism, cellular differentiation and proliferation being crucial in eukaryotic signaling (194-
197). Tribbles proteins are highly conserved, have a MEK1 binding domain and regulate the 
MAPK signaling pathway (177, 198, 199). The Link lab discovered TRIB2 as a FOXO 
repressor protein by conducting a screening for FOXO suppressors (144). It was shown that 
TRIB2 is overexpressed in melanoma cell lines and patients (144), and it confers resistance to 
PI3K and mTOR inhibitors (143). The aim of this master project was to investigate if TRIB2 
confers resistance to MEK inhibitors. 
 
3.1. Characterization of Cell Lines  
3.1.1. TRIB1 and TRIB2 mRNA levels are higher in melanoma cell lines. 
Considering that Tribbles are highly homologs and conserved (200) they can have redundant 
functions. We decided to create isogenic cell lines for TRIB2 to test our hypothesis that TRIB2 
confers resistance to MEK inhibition. Since Tribbles members are highly conserved and 
homolog we decided to investigate the mRNA and protein levels of all three tribbles in 
melanoma and non-melanoma cell lines. If Tribbles have redundant function it means that other 
Tribbles members can compensate TRIB2 depletion.  We characterized a panel of melanoma 
and non-melanoma cell lines (listed in section 2.2). We investigated the mRNA levels, using q-
PCR technique, of all three Tribble members considering that their levels are not described yet 
in melanoma and non-melanoma cell lines. The results were normalized to the non-melanoma 
U2OS cell line (osteosarcoma cells) since this cell line did not show visible TRIB2 protein 
expression by western blot (143). Data was analyzed using Bio Rad CFX manager 3.1 software. 
In general, Tribbles mRNA levels were higher in melanoma cell lines compared to non-
melanoma cell lines U2OS, and HEK293T (figure 3.1). TRIB2 mRNA levels (figure 3.1 A) 
were higher in melanoma cell lines, (except for A375 cell line) than in non-melanoma cells. 
TRIB1 (figure 3.1 B) mRNA levels were higher in melanoma cell lines (except in A375 cells), 
and in HEK293T cells which in turn was slightly higher than in A375 cell line. TRIB3 (Figure 
3.1 C) mRNA levels were higher in melanoma cell lines compared to U2OS cell line. HEK293T 
cell line had the higher TRIB3 mRNA levels.  
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Figure 3.1. Tribbles mRNA levels of a panel of melanoma and non-melanoma cell lines. 
Melanoma cell lines are represented in blue (G361, SK-Mel-28 and A375), U2OS 
(osteosarcoma cell line) is represented in orange and HEK293T (human embryonic kidney cell 
line) is represented in pink. mRNA expression levels were evaluated using RT-PCR and data 
was analyzed using Bio-Rad CFX manager 3.1 software. Y axis represents the fold change 
relative to U2OS cell line. (A) TRIB2 mRNA levels; (B) TRIB1 mRNA levels;) (C) TRIB3 
mRNA levels. Three technical replicates. GAPDH- housekeeping gene. One experiment has 
been performed. 
A B 
C 
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3.1.2. Tribbles protein levels are higher in melanoma cell lines. 
Transcript levels do not always correspond to protein levels. We wondered whether Tribbles 
mRNA levels correlated with protein levels in the panel of cell lines that we used (section 2.2). 
To investigate this, we evaluated the protein expression by western blot using specific 
antibodies (see annex C). Figure 3.2 shows that the expression of all Tribble proteins was higher 
in melanoma cell lines compared to U2OS and HEK293T cell lines. In non-melanoma cell lines, 
the expression of TRIB2 was undetectable, the expression of TRIB1 was similar between 
HEK293T and U2OS cell lines. Interestingly, G361 cell line showed increased TRIB3 
expression in comparison with the remaining melanoma cell lines. Our results indicate that 
TRIB1 and TRIB2 protein expression correlate with mRNA levels. TRIB3 protein levels are in 
fact higher in the panel of melanoma cell lines compared to the non-melanoma cells correlating 
with the transcript levels obtained by RT-PCR. Intriguingly, TRIB3 band in HEK293T cell line 
is very faint compared to the rest of the cell lines, indicative of low expression, but the mRNA 
levels were the highest.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Tribble protein levels in melanoma and non-melanoma cell lines. The first three 
lanes correspond to melanoma cell lines and the two last lanes correspond to HEK293T and 
U2OS cell lines respectively. Protein levels were assessed with Tribble specific antibodies by 
western blot technique. Tubulin was used as a loading control. 20µg total protein loaded per 
lane and separated by 10% SDS-PAGE. One experiment has been performed. 
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3.2 Optimizing Experimental Conditions  
To test the effect of TRIB2 on MEK resistance we have decided to assess cell death induced by 
the MEK inhibitor (Refametinib) with different approaches. For that reason, we primarily 
optimized different variables that will influence the success of the following experiments. 
3.2.1. 100nM of Refametinib is sufficient to inhibit MAPK pathway. 
We determined the optimal concentration of Refametinib to use in the different melanoma cell 
lines.  We used two different concentrations 100nM and 1µM (based in previous studies in our 
lab) during drug exposure for 2, 4, 8, and 24 hours (figure 3.3). To confirm the efficacy of MEK 
inhibition, we performed a western blot and analyzed the phosphorylation status of ERK protein 
using a phospho specific antibody against ERK in SK-MEK-28 cell line. ERK is a downstream 
effector of MEK and it is directly phosphorylated by MEK (201, 202). Two hours after 
treatment the MAPK pathway was already inhibited as it can be seen in figure 3.3 by the 
absence of p-ERK signal (figure 3.3). This effect is phosphorylation specific and not due to 
alterations on total protein levels since total ERK levels are maintained. Additionally, 100nM 
of Refametinib was sufficient to inhibit the MAPK pathway. Here we demonstrate that 
Refametinib successfully inhibits MEK1/2 in our melanoma cell lines and that the pathway is 
inhibited as soon as two hours and as long as 24 hours after treatment. 
 
 
Figure 3.3. Effect of Refametinib treatment on MAPK pathway in SK-Mel-28 cell line. 
SK-Mel-28 cell line was treated with Refametinib (BAY766), a selective MEK inhibitor for 
2, 4, 8 and 24 hours using two different concentrations 100nM and 1µM. *NT-Non-treated 
cells. MAPK pathway activation status was evaluated using a phosphor-specific antibody 
against ERK. GAPDH was used as a loading control. 20µg total protein loaded per lane and 
separated by 10% SDS-PAGE. One experiment has been performed. 
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 3.2.2. Refametinib treatment for 72hours induces cell death.  
Our main goal was to study the role of TRIB2 in resistance to MEK inhibition by analyzing the 
effect on cell death. In order to allow cell death to occur and detect it, we decided to test longer 
drug incubation time-points. To this end, we repeated the experiment performed in the previous 
section (3.2.1) but included an additional time point of 72 hours.  
After 72 hours of Refametinib treatment, we documented the overall cells phenotype with bright 
light pictures. Figure 3.4 shows that treatment with the MEK inhibitor reduced cell density 
when compared to DMSO treatment. Cell death is also notably higher in both concentrations, 
compared to the control.  
 
 
 
 
 
 
 
 
 
In order to analyze cell death, we performed Annexin V/PI protocol that allows the detection 
of apoptotic cells using flow cytometry. Annexin V/ PI protocol is used to identify apoptotic 
cells population through differences in plasma membrane integrity and permeability. Etoposide 
is known to induce DNA double strand breaks (ds-breaks) resulting in cell death (203, 204) and 
it is commonly used as a positive control in apoptosis induction experiments. Upon 16 hours 
treatment, Etoposide lead to 12,60% of apoptotic cell death. Refametinib treatment induced cell 
death at both concentrations, being higher with increasing concentration. At 100nM 
concentration, Refametinib induced 13,10%, similar to what we obtained with Etoposide 
(12,60%). The concentration of 1µM of Refametinib treatment for 72hours induced 30,90% of 
cell death (figure 3.5). These results are preliminary data obtained from one experiment that 
have to be confirmed by additional experiments. 
 
 
Figure 3.4. SK-Mel-28 cell line treated with Refametinib for 72hours. SK-Mel-28 cell line 
density and appearance after 72hours of treatment with 100nM or 1μM Refametinib. 
Amplification 100x. Images are representative of three independent experiments. 
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We verified the MAPK pathway status in this experiment to confirm the efficacy of the inhibitor 
Refametinib after 72 hours of incubation. We showed that even 72 hours after treatment the 
MAPK pathway is still turn-off as it can be observed by the lack of p-ERK signal seen in figure 
3.6.  
Since the pathway was still inhibited after 72h of Refametinib treatment, and we were able to 
detect cell death after this period with Annexin V/ PI, we opted for this time-point. Exposure 
to 100nM and 1μM Refametinib potently inhibited the MAPK pathway. Since we were testing 
our hypothesis in several melanoma cell lines with different sensitivities, we decided to use 
both concentrations in future experiments.  
Figure 3.5. Effect of Refametinib treatment on apoptotic cell death in SK-Mel-28 cell 
line. SK-MEL28 cell line was cultured for 72 hours with Refametinib inhibitor and cell death 
was assessed with AnnexinV/PI. The data was obtained with Facs-Calibur using 
CellQuestPro software and analyzed with GraphPad prism6 (one experiment). The Y axis 
represents the percentage of apoptotic cells. The X axis shows the different treatments: 
DMSO (vehicle), different concentrations of Refametinib and Etoposide. One experiment has 
been performed. 
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3.3. Generation of cell lines with different TRIB2 status 
We hypothesized that TRIB2 confers resistance to MEK inhibition. To test our hypothesis, we 
needed a system in which we would have different amounts of TRIB2. To generate such a cell 
system, we decided to abrogate TRIB2 expression using CRISPR-Cas9 technique and reduce 
TRIB2 expression levels using short hairpin RNAs (shRNA) against TRIB2. Both techniques 
were performed in three melanoma cell lines: G61, SK-Mel-28 and A375. We plated the cells 
the day before transfection and transfected different shTRIB2 to obtain TRIB2 knockdowns. 
To generate the TRIB2 knockout we transfected a plasmid coding simultaneously for single 
guide RNA (sgRNA) and Cas9.  Clones were selected and validated by western blot using a 
specific antibody against TRIB2. 
  
Figure 3.6. Effect of Refametinib treatment on MAPK pathway in SK-Mel-28 cell line. SK-
Mel-28 cell line was treated with Refametinib, a selective MEK inhibitor for 4, 24, 48 and 72 
hours using two different concentrations 100nM and 1µM. *NT-Non-treated cells. MAPK 
pathway activation status was evaluated using a phospho-specific antibody against ERK. 
Tubulin was used as a loading control. 20µg total protein loaded per lane and separated by 10% 
SDS-PAGE. One experiment has been performed. 
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3.3.1. A375  
3.3.1.1. A375: TRIB2 Knockdown 
We transfected A375 cell line with five different short hairpins against TRIB2 previously used 
in our lab (144).  All five short hairpins reduced TRIB2 expression as shown in figure 3.7. The 
negative control (shGFP) also seemed to have an effect on TRIB2 expression. For this reason, 
we also included the parental A375 cell line as a control.  
 
 
 
 
 
 
 
 
 
 
 
 
3.3.1.2. Refametinib treatment caused increased cell death in A375 TRIB2 
knockdown.  
Considering that our negative control (shGFP) interfered with TRIB2 expression (figure 3.7), 
we used the parental cell line as a control. A375 cells were treated with 100 nM Refametinib 
for 72 hours and this treatment induced 20% of cell death in the knockdown cell line (shTRIB2 
#1) compared to 13,8% of cell death in the parental cell line (figure 3.8). Using a higher 
concentration (1µM) of Refametinib caused 48,2% of cell death in the knockdown cell line 
compared to 26,7% in the parental cell line (figure 3.8).  This data suggests that TRIB2 confers 
resistance to MEK inhibition. However, as shGFP caused reduced expression of TRIB2 through 
an unknown mechanism we decided to use additional cell lines to confirm the result.  
 
Figure 3.7. TRIB2 Knockdown in A375 cell line. A375 was transfected with five different 
short hairpins against TRIB2. A375 P represents the parental cell line. Short hairpin against 
GFP refers to the negative control. Protein expression levels were analyzed by western blot 
with a specific TRIB2 antibody. Tubulin was used as a loading control. 20µg total protein 
loaded per lane and separated by 10% SDS-PAGE. Images are representative of two 
independent experiments. 
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3.3.2. G361 
3.3.2.1 G361: TRIB2 knockdown  
We tested two different shRNA against TRIB2 in G361 cell line. The shTRIB2 #2 showed to 
be more efficient downregulating TRIB2 expression when compared to shTRIB2 #1 (figure 
3.9). In this cell line the shGFP did not interfere with TRIB2 expression. The following 
experiments were performed using shTRIB2 #2.  
 
 
 
 
 
Figure 3.8. Cell death analysis of Refametinib treatment in A375 TRIB2 Knockdown cell 
line. The different cell lines are represented in different shades of blue: white corresponds to 
A375 parental cell line (A375P), grey to the control transfected with shRNA against GFP 
(shGFP) and the black to the A375 TRIB2 knockdown (shTRIB2 #1). Red arrows sign the 
percentage of cell death in A375 P and the TRIB2 knockdown (#shTRIB2 1) cell line under 
Refametinib (BAY766) treatment. Etoposide was used at 50 µM for 48 hours. The Y axis 
shows the percentage of dead cells and in X axis the different treatments. Cell death was 
analyzed with trypan blue cell death counting. Results were analyzed with GraphPad prism6. 
NT- non-treated cells. Graph represents one experiment. 
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3.3.2.2.  Refametinib caused increased cell death in G361 TRIB2 knockdown.  
We next tested the effect of TRIB2 upon Refametinib treatment. To this end we used G361 
shTRIB2 #2 cell line (figure 3.9) and analyzed cell death with trypan blue cell death counting 
(as mentioned in section 2.1) and also with PI staining.  
G361 shTRIB2 #2 knockdown treated with 100nM of Refametinib for 72 hours induced a 
modest increase in cell death (29%) compared to the control (shGFP) (21,7% of cell death) 
(figure 3.10). At 1µM concentration cell death was high in both cell lines suggesting that this 
concentration was cytotoxic for G361 cell line causing unspecific cell death. 
 
 
 
 
 
 
 
Figure 3.9. TRIB2 Knockdown in G361 cell line. G361 cell line was transfected with two 
different shRNA against TRIB2 (shTRIB2 #1 and shTRIB2 #2). Negative control refers to short 
hairpin against GFP (shGFP) and parental cell line is represented by G361P. Western blot using 
an antibody specific to TRIB2; GAPDH was used as a loading control. 20µg total protein loaded 
per lane and separated by 10% SDS-PAGE. Images are representative of two independent 
experiments. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During cell death, cells undergo plasma membrane changes, allowing the PI, fluorochrome, to 
pass thought it and bind to DNA, displaying fluorescence. We analyzed the percentage of 
SubG1 cells as an indicator of cell death in FACs Calibur using CellQuestPro software after 
staining with PI.  
This analysis revealed a significant difference in cell death between the G361 shTRIB2 #2 
(586%) and the control shGFP (26,7%) upon treatment with 100nM of Refametinib (figure 
3.11). This difference was also evident with a higher concentration of MEK inhibitor, although 
the difference was only 10%.  In fact, using 1µM Refametinib cell death in G361 shGFP caused 
48% of cell death. These observations may indicate that 1µM is cytotoxic for G361 cell lines. 
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Figure 3.10. Cell death analysis of Refametinib treatment in TRIB2 knockdown. G361 
shGFP (in grey) and G361 shTRIB2 #2 (in black) were treated with Refametinib for 72 hours. 
Cell death was assessed by trypan blue exclusion test. Etoposide was used at 50 µM for 48 
hours as a positive control. Y axis shows the percentage of dead cells and X axis the different 
treatments. Results were analyzed with GraphPad prism6. Graph represents one experiment. 
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3.3.2.3. G361: TRIB2 Knockout 
We screened thirteen G361 clones for TRIB2 knockout. Clones were tested assessing protein 
levels with a specific TRIB2 antibody by western blot. Figure 3.12 shows five clones including. 
Clone #14 which was positive for TRIB2 knockout.  
  
 
 
 
 
 
 
 
 
G 3 6 1 : B A Y 7 6 6  t re a tm e n t  fo r  7 2 h
%
S
u
b
G
1
 C
e
ll
s
D
M
S
O
B
A
Y
7
6
6
 1
0
0
n
M
B
A
Y
7
6
6
 1
µ
M
E
to
p
o
s
id
e
 5
0
 µ
M
0
2 0
4 0
6 0
8 0
G 3 6 1  sh G F P
G 3 6 1  s h T R IB 2  2
Figure 3.12. TRIB2 Knockout (KO) in G361 cell line. The first lane shows G361 
parental cell line followed by different G361 clones for TRIB2 KO. Clone #14 was a 
positive KO for TRIB2 Protein levels were evaluated by western blot using a specific 
antibody against TRIB2. GAPDH was used as a loading control. 20µg total protein 
loaded per lane and separated by 10% SDS-PAGE. One experiment has been performed. 
 
Figure 3.11. PI staining of G361 cell line upon Refametinib treatment. G361 shGFP (in 
grey) and G361 shTRIB2 #2 (in black) were treated with Refametinib for 72 hours. Percentage 
of SubG1 cells was obtained after PI staining and analyzed with BD FACs Calibur and 
CellQuest software. Etoposide was used at 50 µM for 48 hours. Y axis shows the percentage 
of SubG1 cells and the X axis the different treatments. Results were analyzed with GraphPad 
prism6. Graph represents one experiment 
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3.3.2.4. Refametinib caused increased cell death in G361 TRIB2 knockout. 
We used G361 #14, a KO for TRIB2 (figure 3.12) and the parental cell line G361 to quantify 
cell death using trypan blue exclusion test. Results from this experiment were very similar to 
the ones obtained using G361 TRIB2 knockdown (figure 3.11). Refametinib treatment at 
100nM caused 33% of cell death in the knockout cell line and 22% in the parental cell line 
(figure 3.13). As in the previous experiment with G361 TRIB2 knockdown, the difference in 
cell death between parental cell line and the cell line with TRIB2 depletion, was not detected at 
1µM Refametinib concentration: cell death was high in both cell lines (59,5% in the knockout 
and 66,3% in the parental cell line) which may suggest that this concentration is cytotoxic for 
G361 cell line causing unspecific cell death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. Influence of Refametinib treatment in cell death using G361 TRIB2 
knockout cells. G361 P (in grey) and G361 KO (in black) were treated with Refametinib for 
72 hours. Cell death was assessed by trypan blue exclusion test. Etoposide was used at 50 µM 
for 48 hours as a positive control. Y axis shows the percentage of dead cells and X axis the 
different treatments. Results were analyzed with GraphPad prism6. Graph represents one 
experiment. 
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3.3.3. SK-Mel-28 cell line 
3.3.3.1. SK-Mel-28: TRIB2 Knockout 
In SK-Mel-28 we screened 15 different clones for TRIB2 knockouts. Clones were tested 
through the analysis of protein expression by Western Blot technique. In this cell line we 
obtained several TRIB2- knockouts: #5A, #40, #1, #6 and #8 with complete TRIB2 abrogation 
(figure 3.14). We selected a positive TRIB2 knockout clone: SK-Mel-28 #8 to be used in the 
following experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
3.3.3.2. Refametinib treatment in SK-Mel-28 with different levels of TRIB2 shows 
that cell death correlates with TRIB2. 
To test the effect of TRIB2 expression after MEK inhibition we used SK-Mel-28 #8 TRIB2 KO 
cell line and analyzed the cell death percentage upon 72 hours of Refametinib treatment Results 
were analyzed by trypan blue cell death counting and PI staining.  
In order to determine the effect of the vecle on cell viability we treated the cells with DMSO 
and observed that, cell death was similar between parental cell line (9,11%) and the knockout 
cell line (11,56%) (figure 3.15). Etoposide induced 40% of cell death in the parental cell line. 
In the parental cell line, the difference in cell death between the higher and the lower 
concentration of Refametinib treatment was 23,4% and was statistically significant, (*p≤0.05). 
Comparing both cell lines, 1 µM of Refametinib treatment induced a higher percentage of cell 
death in the SK-Mel-28 TRIB2 knockout, statistically significant(*p≤0.05). In the presence of 
Figure 3.14. TRIB2 Knockout (KO) in SK-Mel-28 cell line. The first lane shows SK-Mel-
28 parental cell line TRIB2 followed by different SK-Mel-28 clones for TRIB2 KO. Protein 
levels were evaluated by western blot using a specific antibody against TRIB2. GAPDH was 
used as a loading control. 20µg total protein loaded per lane and separated by 10% SDS-
PAGE. One experiment has been performed.  
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TRIB2 (parental cell line), 1µM of Refametinib caused cell death in 30,2% of cells while the 
cell line where TRIB2 has been depleted Refametinib caused death in 76,9% of the cells, a 2.5 
fold increase c. (figure 3.15). These results strongly suggest that TRIB2 is conferring resistance 
to MEK inhibition. 
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The difference in cell death between both cell lines was also detected with PI staining. Results 
show that, under the same conditions, Refametinib treatment for 72 hours caused more cell 
death in cells with TRIB2 depletion. Comparing both cell lines, using 100nM Refametinib, the 
percentage of SubG1 cells in parental cell line was only 5,9% compared to 22% in the knockout 
cell line (3.7 times more cell death in the TRIB2 knockout cell line). This difference was also 
detected using a high concentration of our drug (1µM) causing 22% cell death in parental cell 
line compared to 47% in the knockout (figure 3.16).  
Figure 3.15. Cell death analysis of Refametinib treatment in TRIB2 knockout. SK-Mel-
28 P (in grey) and SK-Mel-28 KO (in black) were treated with Refametinib for 72 hours. 
Cell death was assessed by trypan blue exclusion test. Etoposide was used at 50 µM for 48 
hours as a positive control. Y axis shows the percentage of dead cells and X axis the different 
treatments. Results were analyzed with GraphPad prism6. Standard Deviation (SD) is present 
in the graph. Results were analyzed with two-way anova (ANOVA) and Bonferroni 
correction in GraphPad prism6. *p≤0.05; **p≤0.01; ***p≤0.001. NT=non-treated cells.  
Graph represents two independent experiments. 
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In our negative control, DMSO treatment, cell death was also higher in the TRIB2 knockout 
cell line (7%) compared to the parental cell line (0,5%) which may indicate that DMSO can be 
more toxic to this cell line. However, this difference is not high. Also the positive control, 
caused 15,6% of cell death in the TRIB2 knockout cell line, and 12,2% in the parental cell line, 
also a minimal difference. The difference in cell death due to Refametinib treatment was more 
than the double comparing both cell lines. Refametinib Results from SK-Mel-28 TRIB2 
knockout cell line demonstrated that TRIB2 presence correlated with cell death Yet, this 
experiment should be repeated. 
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Figure 3.16. Cell death analysis after 72hours of Refametinib treatment in SK-Mel-28 
TRIB2 KO cell line. The different cell lines are represented in different colors: grey 
corresponds to SK-Mel-28 parental cell line, represented by SK-Mel-28P and black to the SK-
Mel-28 TRIB2 knockout cell line, represented by SK-Mel-28 KO. The positive control for cell 
death was 50 µM Etoposide for 48 hours. Y axis shows the percentage of SubG1 cells and in 
X axis the different treatments applied in these cell lines. % of SubG1 cell line was achieved 
using BD FACs Calibur and CellQuest software. Results were analyzed with GraphPad 
prism6. Graph represents one experiment. 
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3.3.3.3.SK-Mel-28: TRIB2 Knock-In 
The fact that we have data that strongly indicates that TRIB2 confers resistance to MEK 
inhibition, MEK inhibition prompts us to study the underlying molecular mechanism. In order 
to perform experiments like Co-Immunoprecipitation to test protein-protein interaction or 
protein localization assays upon MEK inhibitor treatment using the endogenous TRIB2 protein, 
we seek to generate TRIB2-FLAG Knock-In (KI) using the CRISPR-Cas9 system. Similar to 
the knockout, a knock-in can be obtained with the introduction of the same tools into the cell, 
a sgRNA and a Cas9 protein, plus an oligo, a DNA sequence to serve as a template to the 
Homology Direct repair mediated by the CAS9 (187). FLAG is a tag used for the study of 
structural and functional protein properties (205).  
 
We screened 63 clones for A375 cell line, 23 clones for SK-Mel-28 cell line and clones for 
G361 cell line are yet to be tested. We obtained positive TRIB2-FLAG knock-in for SK-Mel-
28 cell line (figure 3.17). In figure 3.17 we show some of the clones tested for TRIB2-FLAG 
knock-in. Clone #13 was a positive knock-in that expresses both TRIB2 and FLAG. The other 
two clones #12 and #15 have a less strong expression of TRIB2 and FLAG. 
 
   
Figure 3.17. TRIB2-FLAG Knock-In (KI) in SK-Mel-28 cell line. The first lane shows SK-
Mel-28 parental cell line (SK-Mel-28 P) followed by different SK-Mel-28 clones marked by 
# and its number for TRIB2 KI. Red arrows show a positive Knock-In for TRIB2-FLAG. 
Protein levels were evaluated by western blot using specific antibodies against TRIB2 and 
FLAG. GAPDH was used as a loading control. 20µg total protein loaded per lane and 
separated by 10% SDS-PAGE. One experiment has been performed. 
 
SK-Mel-28 #13 was a positive TRIB2-FLAG KI (red arrows). Protein levels were analyzed 
by Western Blot. GAPDH was used as a loading control. (20µg total protein loaded per lane 
and separated by 10% SDS-PAGE). 
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4. Discussion 
 
Melanoma is one of the deadliest cancers mainly due to its highly metastatic propensity, 
frequent relapses and its high resistance to therapy (22, 24). Melanomas are highly resistant to 
therapies, and despite all the scientific advances this is still a major concern in public health. 
The clinical benefit from current therapies applied in Melanoma is quite limited (73, 103) and 
understanding the resistance mechanisms, is crucial to improve therapies and the outcome of 
melanoma patients. Here we provide evidences that TRIB2 confers resistance to MEK 
inhibition in melanoma. Based on  the fact that (a) TRIB2 has a MEK1 binding site; (b)  TRIB2 
is overexpressed in melanoma (144) and (c) TRIB2 confers resistance to some PI3K and mTOR 
inhibitors (143) we hypothesized that TRIB2 confers resistance to MEK inhibitors. 
We first analyzed Tribbles expression on a panel of melanoma and non-melanoma cell lines 
and decided which cell system would be a better option to test our hypothesis. Tribbles mRNA 
levels are higher in melanoma cell lines compared to non-melanoma cell lines (U2OS and 
HEK293T). Studies demonstrate that Tribbles are highly conserved and display also a high 
degree of similarity between the human Tribbles amino acid sequences being TRIB1/TRIB2 
71,3%, TRIB1/TRIB3 53,3% and TRIB2/TRIB3 53,7% conserved (158, 206). It has been 
reported that the expression of both TRIB1 and TRIB2 induces AML in mice (164).  This 
similarity between TRIB1/TRIB2 and their oncogenic activities in AML suggest redundant 
functions, but a formal proof for this hypothesis remains to be established.  
Protein levels of the three tribbles members were higher in melanoma cell lines compared to 
the non-melanoma cell lines U2OS and HEK293T that, overall, correlates with our RT-PCR 
data. Surprisingly, the band for TRIB3 protein levels in HEK293T cell line was very faint 
comparing to the TRIB3 mRNA expression data. TRIB3 is mostly regulated at the 
transcriptional level (207) which may explain the difference between mRNA and protein levels 
in HEK293T cell line. The levels of mRNA not always correlate with the protein levels possibly 
due to post-transcriptional mechanisms, such as transcript turnover and the action of micro 
RNAs (miRNAs), and the fact that proteins can have different half-lives (208). Also, the 
absence of correlation can be due to errors and noise from both experiments to detect mRNA 
and protein expression (208). According to previous studies, TRIB2 protein levels were low in 
U2OS cells (143) , consistent with our data. Soubeyrand et al., presented evidences that TRIB1 
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may be post-translationally regulated. Nonetheless, the authors did not detect TRIB1 protein 
expression in HEK293T cell line as in our data (209).  
Overall, in our cell line panel mRNA levels correlated with protein levels. Okamoto H. et al., 
showed that Tribbles members are differentially expressed in different tissues (210) and that 
the expression of TRIB1 and TRIB2 did not change in mice with TRIB3 depletion, indicating 
the absence of a compensatory mechanism(210). This initial data shows that different 
melanoma cell lines have high endogenous TRIB2 levels. For this reason, we decided to 
downregulate and abrogate TRIB2 expression in this melanoma cell line panel, creating two 
different cell systems with the same genetic background and different levels of TRIB2. These 
tools were fundamental to test the effect of TRIB2 mediated resistance to MEK inhibitors. To 
this end, we used Refametinib, a non-ATP competitive MEK1/2 inhibitor that showed to reduce 
proliferation in some cell lines, including SK-Mel-28 and A375 (211, 212).  
Refametinib successfully inhibited MAPK pathway and induced cell death. In our 
experimental conditions, the MAPK pathway was inhibited after Refametinib treatment since 
we did not detect p-ERK upon MEK inhibition. This inhibitory effect is specific and not due to 
changes on total ERK levels. Moreover, we can conclude that the lowest concentration of 
Refametinib was enough to inhibit MAPK pathway. In fact, also the lowest concentration of 
Refametinib was enough to induce cell death in melanoma cell line. After 72hours of 
Refametinib treatment, the percentage of cell death was similar to the one generated by 
Etoposide (positive cell death control) treatment. The  MAPK pathway was still inhibited after 
72 hours of Refametinib treatment. The half maximal inhibitory concentration (IC50) , 
measured by the incorporation of radioactive phosphate from ATP into ERK as substrate,  for 
Refametinib is between 19nM (MEK1) and 47 nM (MEK2) (211). In Hepatocellular carcinoma 
cell lines Refametinib had an half-maximum inhibitory concentration values between 33nM to 
762nM (213) Here, we demonstrated that 100nM Refametinib inhibited MAPK signaling in 
melanoma cell lines.  
TRIB2 downregulation was successful in G361 melanoma cell line, using shTRIB2 #2. 
TRIB2 knockdown was performed in all three melanoma cell lines, since they have high 
endogenous TRIB2 levels. We successfully downregulated TRIB2 expression in A375 cell line. 
However, the negative control shRNA against GFP also interfered with TRIB2 expression. The 
RNAi mediated silencing is time consuming and associated with off-target effects (183).  Many 
studies have shown a RNAi can silence several transcripts (214, 215) due to partial 
complementarity between RNAi and the unintended target (215). Here, probably the shGFP 
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had some homology to TRIB2 mRNA promoting its degradation. To guarantee that our negative 
control would not interfere with our protein of interest, we should have used an empty vector 
instead (183).   
Refametinib treatment caused increased cell death in TRIB2 knockdown cell lines. Using 
the TRIB2 knockdowns cell lines, our preliminary data shows that TRIB2 may be in fact 
conferring resistance to MEK inhibitors. Refametinib treatment induced an increase in cell 
death in the A375 TRIB2 knockdown cell line, comparing to the parental cell line. This 
difference was attenuated when we used lower Refametinib concentrations. This is probably 
due to the fact that there might be residual TRIB2 expression levels that can impact the effect 
of cell death at lower drug concentrations. Iverson C et al., demonstrated that the inhibition of 
A375 cells proliferation, by Refametinib was preferentially by cell cycle arrest rather that 
apoptosis because membrane integrity was maintained in the presence of Refametinib and also 
SubG1 population was very low (211). This might suggest that 100nM Refametinib induced 
cell cycle arrest rather than cell death explaining the fact that under the lower concentration, 
the difference in cell death between both cell lines was lower. G361 TRIB2 knockdown cells 
showed higher cell death levels compared to control cells only at 100nM concentration. In fact, 
treatment of A375 cells with 1µM of Refametinib induced the same amount of cell death than 
the exposure of G361 cells to 100Nm Refametinib. This observation indicates that G361cells 
are more sensitive to MEK inhibition than A375 cells. This was not completely unexpected 
since different cell lines have different tolerance to different drugs. Importantly, PI staining 
showed a higher difference in cell death between the TRIB2 knockdown and the isogenic 
control cells. Using flow cytometry, apoptotic cells stained with PI are hypodiploid (result from 
DNA fragmentation, a characteristic of apoptosis) and detected as a subG1 peak, while normal 
cells are diploid (216, 217). Trypan blue cell death counting is performed manually with a 
Neubauer chamber, which makes this technique more prone to human error. Another factor is 
the time that live cells are in contact with trypan blue that is highly toxic causing increase cell 
death (218, 219) and masking the differences between cell lines with and without TRIB2. This 
problem is overcome with PI staining since cells are fixed immediately after collection.  
Refametinib treatment caused increased cell death in TRIB2 knock-out cell lines. In the 
TRIB2 downregulation system we reduced TRIB2 expression while in the knockout we 
abrogated TRIB2 expression. Results from TRIB2 knockout cells provided further evidence 
that TRIB2 is conferring resistance to Refametinib treatment. In G361 and SK-Mel-28 
melanoma cell we successfully obtained TRIB2 knockouts using the CRISPR Cas9 system.  
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Results obtained from G361 TRIB2 knockouts were quite similar to the ones obtained with 
G361 TRIB2 knockdown: cell death was higher in cells with TRIB2 depletion using 100nM 
Refametinib compared to the control. This difference is higher in the TRIB2 knockout G361 
cell line compared to the G361 TRIB2 knockdown.   
Importantly, SK-Mel-28 TRIB2 knockout cells are more sensitive to the treatment with 100nM 
and 1Μm of Refametinib than the parental cell line, strongly suggesting that TRIB2 mediates 
resistance to MEK inhibitors. Results from SK-MEL-28 cell line reinforced the hypothesis that 
TRIB2 may be conferring resistance to MEK inhibitors.  
TRIB2-FLAG knock-in was successful in SK-Mel-28 cell line. 
We also wanted to characterize the underlying mechanism through how TRIB2 might be 
conferring resistance to MEK inhibition with the analysis of protein-protein interaction and 
protein-localization assays. Having this in mind we tried to generate FLAG-TRIB2 knock-in 
(KI) also using CRISPR-Cas9 system in the same panel of melanoma cell lines. We tested 
several clones and obtained positive FLAG-TRIB2 KI in SK-MeL-28. Consistent with other 
studies (220, 221), we also noted that a gene knock-in using CRISPR-Cas9 was low efficiency 
10-20%. For that reason, we tested several clones from each cell line. Some clones had a weaker 
expression of TRIB2 and FLAG compared to other clones. This can be due to mutations (indels) 
generated during the knock-in process that affects protein expression. Shin SE et al., reported 
that CRISPR-Cas9 knock-in also generates mutations through NHEJ (222). Recent studies 
shows that Homology Direct Repair (HDR) can be favored by the inhibition of NHEJ, 
improving the efficiency of gene editing tools (223).   
The mechanism by which TRIB2 confers resistance to MEK inhibitors remains yet to be 
established. Possible hypothesis are: (a) by direct interaction with MEK, (b) by   regulating 
downstream pro or anti-apoptotic proteins,  (c) by the regulation of other subfamilies of MAPK 
(p38 and JNK) or (d) through a similar mechanism described by Hill et al. (143). A good 
hypothesis would be that, under MEK inhibition, TRIB2 could increase the activation of AKT, 
resulting in PI3K pathway activation. This is a possibility considering that several studies points 
to crosstalk as one of the main causes of treatment resistance because they can counterbalance 
treatment effects (64, 137, 138, 224). Inhibiting one pathway (in this case MAPK) TRIB2 could 
compensate this and activate PI3K pathway with consequent tumor progression. In fact, Jae-
Kyung Won et al., showed that BRAF V600E mutated cells in the presence of a MEK inhibitor 
showed high levels of phosphorylated AKT, while levels of phosphorylated ERK were down 
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suggesting that bypassing ERK signaling to the activation of PI3K pathway leads to resistance 
to the MEK inhibitors (225). Another plausible mechanism would be a direct interaction 
between TRIB2 and MEK1 since TRIB2 has a MEK1 binding domain (177). Also, there are 
several studies showing that TRIB2 regulates MAPKs activity (194), so it is possible that 
TRIB2 might be involved in MEK inhibition-mediated resistance. In addition, it is also possible 
that TRIB2 may confer resistance to MEK inhibitors through the regulation of the other MAPK. 
So far, three main subgroups of MAPK have been identified: ERKS, JNKs and p38-MAPKs 
(annex G). ERKs are essentially involved in cell survival while JNKs and p-38 mediates cell 
stress responses and apoptosis (226-228). JNK and p-38 regulates BCL-2 proteins, including 
BAX, which was already associated with radio resistance (228, 229). Also TRIB2 
overexpression was associated with low levels of BAX in radioresistant cells (229). Another 
interesting fact, is that TRIB2 was found to modulate JNK and p-38 but not ERK1/2 in 
inflammatory bowel disease (197). Moreover, p-38 is activated by MAP kinase kinase (MKK) 
3/6 and JNK by MKK 4/7 while ERK is activated by MEK 1/2. (230-232). p-38 has a dual role 
in apoptosis: promote apoptosis or anti-apoptotic and proliferative effects, demonstrated in 
cancer cells. p-38 increases the malignant potential of cancer cells by increasing proliferation 
and inhibiting apoptosis in prostate cancer (233), breast cancer (234), liver cancer (235), lung 
cancer (236), colon cancer (237) and bladder (238). In some cancers, p38 can play a tumor 
suppressor role (239, 240). Some studies start to demonstrate the role of p38 in melanoma 
tumorigenesis. A study with 8 melanoma cell lines revealed that 7 had both p-ERK and p-38 
activated (241). The same study shows a positive feedback-loop between this 2 pathways 
showing that are both activated in melanoma. Apparently, in melanoma p-38 is required for cell 
migration and proliferation. This means that future treatment should target both pathways (241). 
The inhibition of MAPK pathway by MEK inhibitor can somehow increase p-38 promoting 
cell survival. This hypothesis that TRIB2 may modulate p38 in melanoma promoting resistance 
should be further investigated.  
Here, we show data supports the idea that TRIB2 may be conferring resistance to MEK 
inhibitors: TRIB2 levels correlated with cell death, making it an important therapeutic target in 
melanoma therapy. Understanding the resistance mechanisms to the therapeutic agents can 
improve the outcomes of current therapies and contribute to the development of new therapeutic 
approaches. 
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5. Conclusion and Future Perspectives 
 
Melanoma is the deadliest form of skin cancer, being responsible for 80% of skin cancer deaths. 
Chemoresistance and the high rate of metastasis are the main reasons for treatment failure (15-
17, 21). The identification and characterization of resistance mechanisms to therapies is crucial 
to develop new improved therapies. In the last decade two new therapeutic strategies 
revolutionized the standard care for melanoma patients: immunotherapies based on 
immunocheckpoint inhibitors and targeted therapies including BRAF and MEK inhibitors (17, 
64). Only 30% of the melanoma patients can benefit from immunotherapy because most of the 
patients are intrinsically resistant (17, 64). The development of BRAF inhibitors, such as 
Vemurafenib, improved survival of melanoma patients. Yet, most of the patients who initially 
respond, eventually acquire resistance to this compound (92). A promising strategy is the 
development of new inhibitors for downstream effectors of BRAF, such as MEK. The first 
MEK inhibitor approved for clinical use by the FDA was Trametinib that was proven to be 
clinically effective in the presence of BRAF and NRAS mutations (104, 105). Resistance is a 
major concern in melanoma treatment. The understanding of resistance mechanism should be 
a major concern in cancer treatment. The concept of personalized medicine emerged some years 
ago: a medicine / treatment based on the person’s unique clinical, genetic and environmental 
conditions. In practical terms, means that if we can prove that a given protein is conferring 
resistance to a certain therapy, we can divide population and only administrate the therapy to 
the ones who we predict favorable responses (80, 242). The Link lab has discovered a novel 
resistance mechanism to PI3K and mTOR inhibitors mediated by TRIB2 (143). TRIB2 was 
found to be overexpressed in melanoma and has a MEK binding site in its structure (156, 159). 
Our data provides evidences that TRIB2 is conferring resistance to the MEK inhibitor 
Refametinib, similar to trametinib, making TRIB2 an important target in melanoma therapy. 
Further studies are needed to understand the mechanism by which TRIB2 promotes resistance 
to this drug. A reasonable hypothesis is a similar mechanism to the one described in the PI3K 
pathway (143). Alternatively, the modulation of p38 (the crosstalk between p-ERK and p-38 
promotes cell proliferation and migration in melanoma (241)) and JNK signaling or by direct 
interaction with MEK (197, 241) are also possible mechanisms that can explain this effect.  
In summary, despite the advances in the field of melanoma treatment in the past few years, 
there are still significant obstacles to be overcome that should be treated as a priority in 
melanoma treatment. Understanding the resistance mechanisms to therapeutic agents can 
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certainly improve the outcome of current therapies and contribute to the development of new 
therapeutic approaches. TRIB2 is presented here as potential candidate for MEK inhibition 
mediated resistance, representing an attractive therapeutic target to the development of future 
inhibitors in melanoma. TRIB2 was already suggested as a biomarker that predicts clinical 
responses to melanoma therapy (14). Here, we show further evidences that TRIB2 might be 
useful to predict which patients may benefit from therapy: Patients with TRIB2 overexpression 
may not clinically benefit from PI3K and mTOR inhibitors, MEK inhibitors and possibly to 
other therapies including imunnocheckpoint inhibitors. Future research may be focused on 
improving the risk-benefit of targeted therapies and immunotherapies by understanding the 
resistance mechanisms to these therapies and establishing biomarkers in order to provide 
information about the patient response to the treatment. Hopefully, the ability to distinguish 
patients that may benefit from these treatments may improve the clinical outcome of melanoma 
patients (243). 
  
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
61 
 
6. Bibliographic References  
 
1. Global Burden of Disease Cancer C. THe global burden of cancer 2013. JAMA 
Oncology. 2015;1(4):505-27. 
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et 
al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur 
J Cancer. 2013;49(6):1374-403. 
3. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and 
mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-907. 
4. Martin AM, Weber BL. Genetic and hormonal risk factors in breast cancer. J Natl 
Cancer Inst. 2000;92(14):1126-35. 
5. Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. 
Cancer is a Preventable Disease that Requires Major Lifestyle Changes. Pharmaceutical 
Research. 2008;25(9):2097-116. 
6. Blanpain C. Tracing the cellular origin of cancer. Nat Cell Biol. 2013;15(2):126-34. 
7. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations 
in cancer. Nat Rev Genet. 2013;14(10):703-18. 
8. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer 
Genome Landscapes. Science (New York, NY). 2013;339(6127):1546-58. 
9. Zhu K, Liu Q, Zhou Y, Tao C, Zhao Z, Sun J, et al. Oncogenes and tumor suppressor 
genes: comparative genomics and network perspectives. BMC Genomics. 2015;16 Suppl 7:S8. 
10. Lahtz C, Pfeifer GP. Epigenetic changes of DNA repair genes in cancer. Journal of 
Molecular Cell Biology. 2011;3(1):51-8. 
11. You JS, Jones PA. Cancer Genetics and Epigenetics: Two Sides of the Same Coin? 
Cancer Cell. 2012;22(1):9-20. 
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. 
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
2011;144(5):646-74. 
14. Hill R, Kalathur RK, Colaco L, Brandao R, Ugurel S, Futschik M, et al. TRIB2 as a 
biomarker for diagnosis and progression of melanoma. Carcinogenesis. 2015;36(4):469-77. 
15. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. 
Nature. 2007;445(7130):851-7. 
16. Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. 
Cutaneous malignant melanoma. Mayo Clin Proc. 2006;81(4):500-7. 
17. Winder M, Viros A. Mechanisms of Drug Resistance in Melanoma. Handb Exp 
Pharmacol. 2017. 
18. Lo JA, Fisher DE. The melanoma revolution: from UV carcinogenesis to a new era in 
therapeutics. Science (New York, NY). 2014;346(6212):945-9. 
19. Hirobe T. Keratinocytes regulate the function of melanocytes. Dermatologica Sinica. 
2014;32(4):200-4. 
20. Cichorek M, Wachulska M, Stasiewicz A, Tymińska A. Skin melanocytes: biology and 
development. Advances in Dermatology and Allergology/Postȩpy Dermatologii I Alergologii. 
2013;30(1):30-41. 
21. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene. 
2003;22(20):3138-51. 
22. Kulesa PM, Morrison JA, Bailey CM. The Neural Crest and Cancer: A Developmental 
Spin on Melanoma. Cells, tissues, organs. 2013;198(1):10.1159/000348418. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
62 
 
23. Chung C-Y, Madhunapantula SV, Desai D, Amin S, Robertson GP. Melanoma 
Prevention Using Topical PBISe. Cancer prevention research (Philadelphia, Pa). 
2011;4(6):935-48. 
24. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and 
adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508(7494):118-22. 
25. Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC, Slominski A. Current concepts of 
metastasis in melanoma. Expert review of dermatology. 2008;3(5):569-85. 
26. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of 
rational therapeutics. Journal of Clinical Investigation. 2005;115(4):813-24. 
27. Greenwald HS, Friedman EB, Osman I. Superficial spreading and nodular melanoma 
are distinct biological entities: a challenge to the linear progression model. Melanoma Research. 
2012;22(1):1-8. 
28. McClain SE, Mayo KB, Shada AL, Smolkin ME, Patterson JW, Slingluff CL. 
Amelanotic Melanomas Presenting as Red Skin Lesions: A Diagnostic Challenge with 
Potentially Lethal Consequences. International journal of dermatology. 2012;51(4):420-6. 
29. Kaliki S, Shields CL, Shields JA. Uveal melanoma: Estimating prognosis. Indian 
Journal of Ophthalmology. 2015;63(2):93-102. 
30. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. 
Oncogene. 2007;26(22):3279-90. 
31. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase 
cascade for the treatment of cancer. Oncogene. 2007;26(22):3291-310. 
32. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in 
melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010;80(5):624-
37. 
33. Weinberg R. The Biology of Cancer, Second Edition: Taylor & Francis Group; 2013. 
34. Whitmarsh AJ. Regulation of gene transcription by mitogen-activated protein kinase 
signaling pathways. Biochim Biophys Acta. 2007;1773(8):1285-98. 
35. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling 
pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103-19. 
36. Gomes AR, Zhao F, Lam EWF. Role and regulation of the forkhead transcription factors 
FOXO3a and FOXM1 in carcinogenesis and drug resistance. Chinese Journal of Cancer. 
2013;32(7):365-70. 
37. Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways 
causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in 
pancreatic cancer. J Mol Signal. 2010;5:10. 
38. McCain J. The MAPK (ERK) Pathway: Investigational Combinations for the Treatment 
Of BRAF-Mutated Metastatic Melanoma. Pharmacy and Therapeutics. 2013;38(2):96-108. 
39. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, et al. Analysis of BRAF and 
N-RAS mutations in metastatic melanoma tissues. Cancer Res. 2003;63(14):3955-7. 
40. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the 
BRAF gene in human cancer. Nature. 2002;417(6892):949-54. 
41. Celebi JT, Shendrik I, Silvers D, Peacocke M. Identification of PTEN mutations in 
metastatic melanoma specimens. Journal of Medical Genetics. 2000;37(9):653-7. 
42. Jakob JA, Bassett RL, Jr., Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS 
mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 
2012;118(16):4014-23. 
43. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et al. 
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 
2004;64(19):7002-10. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
63 
 
44. Balch CM, Gershenwald JE, Soong S-j, Thompson JF, Atkins MB, Byrd DR, et al. Final 
Version of 2009 AJCC Melanoma Staging and Classification. Journal of Clinical Oncology. 
2009;27(36):6199-206. 
45. Sullivan RJ, LoRusso PM, Flaherty KT. The Intersection of Immune-Directed and 
Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will 
Be. Clinical Cancer Research. 2013;19(19):5283. 
46. Raigani S, Cohen S, Boland GM. The Role of Surgery for Melanoma in an Era of 
Effective Systemic Therapy. Curr Oncol Rep. 2017;19(3):17. 
47. Phan GQ, Messina JL, Sondak VK, Zager JS. Sentinel lymph node biopsy for 
melanoma: indications and rationale. Cancer Control. 2009;16(3):234-9. 
48. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final 
Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. The New 
England journal of medicine. 2014;370(7):599-609. 
49. Perez-Herrero E, Fernandez-Medarde A. Advanced targeted therapies in cancer: Drug 
nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52-79. 
50. Baudino TA. Targeted Cancer Therapy: The Next Generation of Cancer Treatment. Curr 
Drug Discov Technol. 2015;12(1):3-20. 
51. Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for 
metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol. 
2010;74(1):27-39. 
52. Bhatia S, Tykodi SS, Thompson JA. Treatment of Metastatic Melanoma: An Overview. 
Oncology (Williston Park, NY). 2009;23(6):488-96. 
53. Sanada M, Takagi Y, Ito R, Sekiguchi M. Killing and mutagenic actions of dacarbazine, 
a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 
mutations. DNA Repair (Amst). 2004;3(4):413-20. 
54. Damia G, D‘Incalci M. Mechanisms of resistance to alkylating agents. Cytotechnology. 
1998;27(1-3):165-73. 
55. Yang AS, Chapman PB. The history and future of chemotherapy for melanoma. 
Hematol Oncol Clin North Am. 2009;23(3):583-97, x. 
56. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in 
the central nervous system, may improve the treatment of advanced metastatic melanoma. 
Oncologist. 2000;5(2):144-51. 
57. Quereux G, Dreno B. Fotemustine for the treatment of melanoma. Expert Opin 
Pharmacother. 2011;12(18):2891-904. 
58. Kondo N, Takahashi A, Ono K, Ohnishi T. DNA damage induced by alkylating agents 
and repair pathways. J Nucleic Acids. 2010;2010:543531. 
59. Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating 
agents used in the treatment of haematological malignancies. Blood Rev. 1992;6(3):163-73. 
60. Grady WM, Ulrich CM. DNA alkylation and DNA methylation: cooperating 
mechanisms driving the formation of colorectal adenomas and adenocarcinomas? Gut. 
2007;56(3):318-20. 
61. Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused 
by alkylating agents. Nat Rev Cancer. 2012;12(2):104-20. 
62. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat 
Rev Cancer. 2008;8(6):473-80. 
63. Luke JJ, Schwartz GK. Chemotherapy in the Management of Advanced Cutaneous 
Malignant Melanoma. Clinics in dermatology. 2013;31(3):290-7. 
64. Meierjohann S. Crosstalk signaling in targeted melanoma therapy. Cancer Metastasis 
Rev. 2017;36(1):23-33. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
64 
 
65. Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma. BMC 
Med. 2016;14:20. 
66. Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical 
potential. Therapeutic Advances in Medical Oncology. 2015;7(2):97-106. 
67. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 
2015;348(6230):69. 
68. Wang R-F, Wang HY. Immune targets and neoantigens for cancer immunotherapy and 
precision medicine. Cell Res. 2017;27(1):11-37. 
69. Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, 
et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature. 
2016;536(7614):91-5. 
70. Haanen JBAG. Immunotherapy of melanoma. EJC Supplements. 2013;11(2):97-105. 
71. Osborn JL, Greer SF. Metastatic Melanoma Cells Evade Immune Detection by 
Silencing STAT1. International Journal of Molecular Sciences. 2015;16(2):4343-61. 
72. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour 
immunogenicity. Nat Rev Cancer. 2012;12(4):307-13. 
73. Fisher R, Larkin J. Vemurafenib: a new treatment for BRAF-V600 mutated advanced 
melanoma. Cancer Management and Research. 2012;4:243-52. 
74. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. 
Immunopharmacology. 1997;37(2-3):117-32. 
75. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of 
melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11(1):24-37. 
76. Tarhini A, Lo E, Minor DR. Releasing the Brake on the Immune System: Ipilimumab 
in Melanoma and Other Tumors. Cancer Biotherapy & Radiopharmaceuticals. 2010;25(6):601-
13. 
77. Raedler LA. Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for 
Unresectable or Metastatic Melanoma. American Health & Drug Benefits. 2015;8(Spec 
Feature):180-3. 
78. Britten CD. PI3K and MEK inhibitor combinations: examining the evidence in selected 
tumor types. Cancer Chemother Pharmacol. 2013;71(6):1395-409. 
79. Atefi M, Avramis E, Lassen A, Wong D, Robert L, Foulad D, et al. Effects of MAPK 
and PI3K Pathways on PD-L1 Expression in Melanoma. Clinical cancer research : an official 
journal of the American Association for Cancer Research. 2014;20(13):3446-57. 
80. Ferreira BI, Hill R, Link W. Special Review: Caught in the Crosshairs: Targeted Drugs 
and Personalized Medicine. Cancer J. 2015;21(6):441-7. 
81. Johnson DB, Puzanov I. Treatment of NRAS-Mutant Melanoma. Current treatment 
options in oncology. 2015;16(4):15-. 
82. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. 
Future Medicinal Chemistry. 2011;3(14):1787-808. 
83. Goldinger SM, Murer C, Stieger P, Dummer R. Targeted therapy in melanoma – the 
role of BRAF, RAS and KIT mutations. EJC Supplements. 2013;11(2):92-6. 
84. Gençler B, Gönül M. Cutaneous Side Effects of BRAF Inhibitors in Advanced 
Melanoma: Review of the Literature. Dermatology Research and Practice. 2016;2016:5361569. 
85. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced 
melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581-
6. 
86. Azijli K, Stelloo E, Peters GJ, AJ VDE. New developments in the treatment of 
metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res. 
2014;34(4):1493-505. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
65 
 
87. Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, et al. Sorafenib and 
dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II 
studies. Br J Cancer. 2011;105(3):353-9. 
88. Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, et al. Phase III trial 
of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 
2013;31(3):373-9. 
89. Sharma A, Shah SR, Illum H, Dowell J. Vemurafenib: targeted inhibition of mutated 
BRAF for treatment of advanced melanoma and its potential in other malignancies. Drugs. 
2012;72(17):2207-22. 
90. Santarpia L, Lippman SL, El-Naggar AK. Targeting the Mitogen-Activated Protein 
Kinase RAS-RAF Signaling Pathway in Cancer Therapy. Expert opinion on therapeutic targets. 
2012;16(1):103-19. 
91. Lacouture ME, O'Reilly K, Rosen N, Solit DB. Induction of cutaneous squamous cell 
carcinomas by RAF inhibitors: cause for concern? J Clin Oncol. 2012;30(3):329-30. 
92. Aplin AE, Kaplan FM, Shao Y. Mechanisms of resistance to RAF inhibitors in 
melanoma. J Invest Dermatol. 2011;131(9):1817-20. 
93. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, et al. Elevated 
CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. 
Cancer Res. 2008;68(12):4853-61. 
94. Goetz EM, Ghandi M, Treacy DJ, Wagle N, Garraway LA. ERK Mutations Confer 
Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors. Cancer research. 
2014;74(23):7079-89. 
95. Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations 
in uncultured melanomas and melanoma cell lines. Oncogene. 1998;16(26):3397-402. 
96. Deichmann M, Thome M, Benner A, Egner U, Hartschuh W, Näher H. PTEN/MMAC1 
expression in melanoma resection specimens. British Journal of Cancer. 2002;87(12):1431-6. 
97. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, et al. MMAC1/PTEN mutations in 
primary tumor specimens and tumor cell lines. Cancer Res. 1997;57(23):5221-5. 
98. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential 
for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 
2012;487(7408):505-9. 
99. Manzano JL, Layos L, Bugés C, de los Llanos Gil M, Vila L, Martínez-Balibrea E, et 
al. Resistant mechanisms to BRAF inhibitors in melanoma. Annals of Translational Medicine. 
2016;4(12):237. 
100. King JW, Nathan PD. Role of the MEK inhibitor trametinib in the treatment of 
metastatic melanoma. Future Oncol. 2014;10(9):1559-70. 
101. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire 
resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 
2010;468(7326):973-7. 
102. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting 
therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 
2011;29(22):3085-96. 
103. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF 
inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 
2011;480(7377):387-90. 
104. Grimaldi AM, Simeone E, Ascierto PA. The role of MEK inhibitors in the treatment of 
metastatic melanoma. Curr Opin Oncol. 2014;26(2):196-203. 
105. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective 
inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U 
S A. 2008;105(8):3041-6. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
66 
 
106. Arcaro A, Guerreiro AS. The Phosphoinositide 3-Kinase Pathway in Human Cancer: 
Genetic Alterations and Therapeutic Implications. Current Genomics. 2007;8(5):271-306. 
107. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. 
Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 
1998;273(29):18623-32. 
108. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench 
to bedside. Journal of Hematology & Oncology. 2013;6:27-. 
109. Narita Y, Okamoto K, Kawada MI, Takase K, Minoshima Y, Kodama K, et al. Novel 
ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma 
harboring the MEK1-C121S mutation in a preclinical model. Mol Cancer Ther. 
2014;13(4):823-32. 
110. Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, et al. Sensitivity to the 
MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN 
status. Mol Cancer. 2012;11:75. 
111. Johnson D. Cell Death Signaling in Cancer Biology and Treatment: Springer New York; 
2012. 
112. Lugowska I, Koseła-Paterczyk H, Kozak K, Rutkowski P. Trametinib: a MEK inhibitor 
for management of metastatic melanoma. OncoTargets and therapy. 2015;8:2251-9. 
113. Hatzivassiliou G, Haling JR, Chen H, Song K, Price S, Heald R, et al. Mechanism of 
MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature. 
2013;501(7466):232-6. 
114. Tran KA, Cheng MY, Mitra A, Ogawa H, Shi VY, Olney LP, et al. MEK inhibitors and 
their potential in the treatment of advanced melanoma: the advantages of combination therapy. 
Drug Design, Development and Therapy. 2016;10:43-52. 
115. Carlino MS, Fung C, Shahheydari H, Todd JR, Boyd SC, Irvine M, et al. Preexisting 
MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. 
Clin Cancer Res. 2015;21(1):98-105. 
116. Poulikakos PI, Solit DB. Resistance to MEK inhibitors: should we co-target upstream? 
Sci Signal. 2011;4(166):pe16. 
117. Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer 
therapy: the long and winding road. Nat Rev Cancer. 2015;15(10):577-92. 
118. Kodaki T, Woscholski R, Hallberg B, Rodriguez-Viciana P, Downward J, Parker PJ. 
The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol. 1994;4(9):798-806. 
119. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR Pathways: Cross-talk 
and Compensation. Trends in biochemical sciences. 2011;36(6):320-8. 
120. Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant 
tumors. The main reason for therapeutic failure. Arzneimittelforschung. 2008;58(6):261-4. 
121. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: 
an evolving paradigm. Nat Rev Cancer. 2013;13(10):714-26. 
122. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug 
Resistance in Cancer: An Overview. Cancers. 2014;6(3):1769-92. 
123. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug 
resistance. Oncogene. 0000;22(47):7369-75. 
124. Sheehan D, Meade G, Foley VM, Dowd CA. Structure, function and evolution of 
glutathione transferases: implications for classification of non-mammalian members of an 
ancient enzyme superfamily. Biochemical Journal. 2001;360(Pt 1):1-16. 
125. Tew KD, Monks A, Barone L, Rosser D, Akerman G, Montali JA, et al. Glutathione-
associated enzymes in the human cell lines of the National Cancer Institute Drug Screening 
Program. Mol Pharmacol. 1996;50(1):149-59. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
67 
 
126. Grossman D, Altieri DC. Drug resistance in melanoma: mechanisms, apoptosis, and 
new potential therapeutic targets. Cancer Metastasis Rev. 2001;20(1-2):3-11. 
127. Anasagasti MJ, Martin JJ, Mendoza L, Obrador E, Estrela JM, McCuskey RS, et al. 
Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic 
microvasculature. Hepatology. 1998;27(5):1249-56. 
128. Hande KR. Topoisomerase II inhibitors. Update on Cancer Therapeutics. 2008;3(1):13-
26. 
129. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nature reviews 
Cancer. 2009;9(5):338-50. 
130. Lage H, Helmbach H, Dietel M, Schadendorf D. Modulation of DNA topoisomerase II 
activity and expression in melanoma cells with acquired drug resistance. Br J Cancer. 
2000;82(2):488-91. 
131. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human 
melanoma. Int J Cancer. 2001;93(5):617-22. 
132. Fukunaga-Kalabis M, Herlyn M. Beyond ABC: another mechanism of drug resistance 
in melanoma side population. The Journal of investigative dermatology. 2012;132(10):2317-9. 
133. van der Pol MA, Broxterman HJ, Pater JM, Feller N, van der Maas M, Weijers GW, et 
al. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast 
cancer resistance protein, in minimal residual disease in acute myeloid leukemia. 
Haematologica. 2003;88(2):134-47. 
134. Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, et al. 
Membrane transport proteins associated with drug resistance expressed in human melanoma. 
Am J Pathol. 1995;147(6):1545-52. 
135. Runger TM, Emmert S, Schadendorf D, Diem C, Epe B, Hellfritsch D. Alterations of 
DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. J Invest 
Dermatol. 2000;114(1):34-9. 
136. Pepponi R, Marra G, Fuggetta MP, Falcinelli S, Pagani E, Bonmassar E, et al. The effect 
of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of 
human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J 
Pharmacol Exp Ther. 2003;304(2):661-8. 
137. Sun X, Bao J, You Z, Chen X, Cui J. Modeling of signaling crosstalk-mediated drug 
resistance and its implications on drug combination. Oncotarget. 2016;7(39):63995-4006. 
138. Prahallad A, Bernards R. Opportunities and challenges provided by crosstalk between 
signalling pathways in cancer. Oncogene. 2016;35(9):1073-9. 
139. Elmore S. Apoptosis: A Review of Programmed Cell Death. Toxicologic pathology. 
2007;35(4):495-516. 
140. Helmbach H, Sinha P, Schadendorf D. Human melanoma: drug resistance. Recent 
Results Cancer Res. 2003;161:93-110. 
141. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochimica et 
biophysica acta. 2010;1805(1):105. 
142. Somasundaram R, Villanueva J, Herlyn M. Intratumoral Heterogeneity as a Therapy 
Resistance Mechanism: Role of Melanoma Subpopulations. Advances in pharmacology (San 
Diego, Calif). 2012;65:335-59. 
143. Hill R, Madureira PA, Ferreira B, Baptista I, Machado S, Colaço L, et al. TRIB2 confers 
resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT. Nature 
Communications. 2017;8:14687. 
144. Zanella F, Renner O, Garcia B, Callejas S, Dopazo A, Peregrina S, et al. Human TRIB2 
is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. 
Oncogene. 2010;29(20):2973-82. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
68 
 
145. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes 
tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 
2008;10(2):138-48. 
146. Yang J-Y, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes 
tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nature cell biology. 
2008;10(2):138-48. 
147. Daitoku H, Sakamaki J-i, Fukamizu A. Regulation of FoxO transcription factors by 
acetylation and protein–protein interactions. Biochimica et Biophysica Acta (BBA) - Molecular 
Cell Research. 2011;1813(11):1954-60. 
148. Martins R, Lithgow GJ, Link W. Long live FOXO: unraveling the role of FOXO 
proteins in aging and longevity. Aging Cell. 2016;15(2):196-207. 
149. Calnan DR, Brunet A. The FoxO code. Oncogene. 0000;27(16):2276-88. 
150. Zhang X, Tang N, Hadden TJ, Rishi AK. Akt, FoxO and regulation of apoptosis. 
Biochim Biophys Acta. 2011;1813(11):1978-86. 
151. Jagani Z, Singh A, Khosravi-Far R. FoxO Tumor Suppressors and BCR-ABL-Induced 
Leukemia: A Matter of Evasion of Apoptosis. Biochimica et biophysica acta. 2008;1785(1):63-
84. 
152. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. 
Identification of a tumour suppressor network opposing nuclear Akt function. Nature. 
2006;441(7092):523-7. 
153. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, et al. Knockdown 
of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of 
FOXO3a activity. Oncogene. 2007;26(55):7647-55. 
154. Cornforth AN, Davis JS, Khanifar E, Nastiuk KL, Krolewski JJ. FOXO3a mediates the 
androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP 
cells. Oncogene. 2008;27(32):4422-33. 
155. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell 
survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 
1999;96(6):857-68. 
156. Dobens LL, Jr., Bouyain S. Developmental roles of tribbles protein family members. 
Dev Dyn. 2012;241(8):1239-48. 
157. Eyers PA, Keeshan K, Kannan N. Tribbles in the 21st Century: The Evolving Roles of 
Tribbles Pseudokinases in Biology and Disease. Trends Cell Biol. 2016. 
158. Cunard R. Mammalian tribbles homologs at the crossroads of endoplasmic reticulum 
stress and Mammalian target of rapamycin pathways. Scientifica (Cairo). 2013;2013:750871. 
159. Sakai S, Miyajima C, Uchida C, Itoh Y, Hayashi H, Inoue Y. Tribbles-Related Protein 
Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer 
Development. Curr Cancer Drug Targets. 2016;16(2):147-56. 
160. Bailey FP, Byrne DP, Oruganty K, Eyers CE, Novotny CJ, Shokat KM, et al. The 
Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent 
manner. The Biochemical journal. 2015;467(1):47-62. 
161. Guan H, Shuaib A, Leon DDD, Angyal A, Salazar M, Velasco G, et al. Competition 
between members of the tribbles pseudokinase protein family shapes their interactions with 
mitogen activated protein kinase pathways. Scientific Reports. 2016;6:32667. 
162. Salazar M, Lorente M, García-Taboada E, Pérez Gómez E, Dávila D, Zúñiga-García P, 
et al. Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO 
inactivation. Cell Death and Differentiation. 2015;22(1):131-44. 
163. Stein Sarah J, Mack Ethan A, Rome Kelly S, Pear Warren S. Tribbles in normal and 
malignant haematopoiesis. Biochemical Society Transactions. 2015;43(5):1112-5. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
69 
 
164. Dedhia PH, Keeshan K, Uljon S, Xu L, Vega ME, Shestova O, et al. Differential ability 
of Tribbles family members to promote degradation of C/EBPalpha and induce acute 
myelogenous leukemia. Blood. 2010;116(8):1321-8. 
165. Keeshan K, Bailis W, Dedhia PH, Vega ME, Shestova O, Xu L, et al. Transformation 
by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. Blood. 
2010;116(23):4948-57. 
166. Salazar M, Lorente M, Garcia-Taboada E, Perez Gomez E, Davila D, Zuniga-Garcia P, 
et al. Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO 
inactivation. Cell Death Differ. 2015;22(1):131-44. 
167. Lourenco AR, Coffer PJ. A tumor suppressor role for C/EBPalpha in solid tumors: more 
than fat and blood. Oncogene. 2017. 
168. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and 
regulation. Biochemical Journal. 2002;365(Pt 3):561-75. 
169. Strimbu K, Tavel JA. What are Biomarkers? Current opinion in HIV and AIDS. 
2010;5(6):463-6. 
170. Mayeux R. Biomarkers: Potential Uses and Limitations. NeuroRx. 2004;1(2):182-8. 
171. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and 
validation. Translational cancer research. 2015;4(3):256-69. 
172. Ballman KV. Biomarker: Predictive or Prognostic? Journal of Clinical Oncology. 
2015;33(33):3968-71. 
173. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life 
Sci. 1999;55(1):96-107. 
174. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. 
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 
1993;362(6423):857-60. 
175. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. 
Nature. 1997;387(6630):296-9. 
176. Kubbutat MH, Vousden KH. Proteolytic cleavage of human p53 by calpain: a potential 
regulator of protein stability. Mol Cell Biol. 1997;17(1):460-8. 
177. Foulkes DM, Byrne DP, Bailey FP, Eyers PA. Tribbles pseudokinases: novel targets for 
chemical biology and drug discovery? Biochem Soc Trans. 2015;43(5):1095-103. 
178. Deepak SA, Kottapalli KR, Rakwal R, Oros G, Rangappa KS, Iwahashi H, et al. Real-
Time PCR: Revolutionizing Detection and Expression Analysis of Genes. Current Genomics. 
2007;8(4):234-51. 
179. Garibyan L, Avashia N. Research Techniques Made Simple: Polymerase Chain 
Reaction (PCR). The Journal of investigative dermatology. 2013;133(3):e6-e. 
180. Mahmood T, Yang P-C. Western Blot: Technique, Theory, and Trouble Shooting. North 
American Journal of Medical Sciences. 2012;4(9):429-34. 
181. Ernst O, Zor T. Linearization of the Bradford Protein Assay. Journal of Visualized 
Experiments : JoVE. 2010(38):1918. 
182. Carlsson N, Borde A, Wolfel S, Kerman B, Larsson A. Quantification of protein 
concentration by the Bradford method in the presence of pharmaceutical polymers. Anal 
Biochem. 2011;411(1):116-21. 
183. Moore CB, Guthrie EH, Huang MT-H, Taxman DJ. Short Hairpin RNA (shRNA): 
Design, Delivery, and Assessment of Gene Knockdown. Methods in molecular biology 
(Clifton, NJ). 2010;629:141-58. 
184. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs 
(shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002;16(8):948-
58. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
70 
 
185. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using 
the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281-308. 
186. Chen S, Sun H, Miao K, Deng C-X. CRISPR-Cas9: from Genome Editing to Cancer 
Research. International Journal of Biological Sciences. 2016;12(12):1427-36. 
187. He X, Tan C, Wang F, Wang Y, Zhou R, Cui D, et al. Knock-in of large reporter genes 
in human cells via CRISPR/Cas9-induced homology-dependent and independent DNA repair. 
Nucleic Acids Res. 2016;44(9):e85. 
188. Hopp TP, Prickett KS, Price VL, Libby RT, March CJ, Pat Cerretti D, et al. A Short 
Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification. 
Nat Biotech. 1988;6(10):1204-10. 
189. Lobbestael E, Reumers V, Ibrahimi A, Paesen K, Thiry I, Gijsbers R, et al. 
Immunohistochemical detection of transgene expression in the brain using small epitope tags. 
BMC Biotechnology. 2010;10:16-. 
190. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for 
apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells 
using fluorescein labelled Annexin V. J Immunol Methods. 1995;184(1):39-51. 
191. Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J 
Immunol Methods. 2000;243(1-2):167-90. 
192. Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR. Modified annexin V/propidium 
iodide apoptosis assay for accurate assessment of cell death. J Vis Exp. 2011(50). 
193. Fadok VA, Bratton DL, Frasch SC, Warner ML, Henson PM. The role of 
phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ. 
1998;5(7):551-62. 
194. Kiss-Toth E, Bagstaff SM, Sung HY, Jozsa V, Dempsey C, Caunt JC, et al. Human 
tribbles, a protein family controlling mitogen-activated protein kinase cascades. J Biol Chem. 
2004;279(41):42703-8. 
195. Liang KL, Paredes R, Carmody R, Eyers PA, Meyer S, McCarthy TV, et al. Human 
TRIB2 Oscillates during the Cell Cycle and Promotes Ubiquitination and Degradation of 
CDC25C. Int J Mol Sci. 2016;17(9). 
196. Keeshan K, He Y, Wouters BJ, Shestova O, Xu L, Sai H, et al. Tribbles homolog 2 
(Trib2) inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer cell. 
2006;10(5):401-11. 
197. Wei SC, Rosenberg IM, Cao Z, Huett AS, Xavier RJ, Podolsky DK. Tribbles 2 (Trib2) 
is a novel regulator of toll-like receptor 5 signaling. Inflamm Bowel Dis. 2012;18(5):877-88. 
198. Wang J, Park JS, Wei Y, Rajurkar M, Cotton JL, Fan Q, et al. TRIB2 acts downstream 
of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPalpha function. Mol Cell. 
2013;51(2):211-25. 
199. Yokoyama T, Kanno Y, Yamazaki Y, Takahara T, Miyata S, Nakamura T. Trib1 links 
the MEK1/ERK pathway in myeloid leukemogenesis. Blood. 2010;116(15):2768-75. 
200. Guan H, Shuaib A, Leon DD, Angyal A, Salazar M, Velasco G, et al. Competition 
between members of the tribbles pseudokinase protein family shapes their interactions with 
mitogen activated protein kinase pathways. Sci Rep. 2016;6:32667. 
201. Seger R, Ahn NG, Posada J, Munar ES, Jensen AM, Cooper JA, et al. Purification and 
characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-
stimulated A431 cells. J Biol Chem. 1992;267(20):14373-81. 
202. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate 
diverse cellular functions. Growth Factors. 2006;24(1):21-44. 
203. Schonn I, Hennesen J, Dartsch DC. Cellular responses to etoposide: cell death despite 
cell cycle arrest and repair of DNA damage. Apoptosis. 2010;15(2):162-72. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
71 
 
204. Jamil S, Lam I, Majd M, Tsai S-H, Duronio V. Etoposide induces cell death via 
mitochondrial-dependent actions of p53. Cancer Cell International. 2015;15:79. 
205. Einhauer A, Jungbauer A. The FLAG peptide, a versatile fusion tag for the purification 
of recombinant proteins. J Biochem Biophys Methods. 2001;49(1-3):455-65. 
206. Yokoyama T, Nakamura T. Tribbles in disease: Signaling pathways important for 
cellular function and neoplastic transformation. Cancer Sci. 2011;102(6):1115-22. 
207. Ohoka N, Yoshii S, Hattori T, Onozaki K, Hayashi H. TRB3, a novel ER stress-
inducible gene, is induced via ATF4–CHOP pathway and is involved in cell death. The EMBO 
Journal. 2005;24(6):1243-55. 
208. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance 
and mRNA expression levels on a genomic scale. Genome Biol. 2003;4(9):117. 
209. Soubeyrand S, Martinuk A, Lau P, McPherson R. TRIB1 Is Regulated Post-
Transcriptionally by Proteasomal and Non-Proteasomal Pathways. PLoS ONE. 
2016;11(3):e0152346. 
210. Okamoto H, Latres E, Liu R, Thabet K, Murphy A, Valenzeula D, et al. Genetic deletion 
of Trb3, the mammalian Drosophila tribbles homolog, displays normal hepatic insulin signaling 
and glucose homeostasis. Diabetes. 2007;56(5):1350-6. 
211. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, et al. RDEA119/BAY 
869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer 
Res. 2009;69(17):6839-47. 
212. Chang Q, Chapman MS, Miner JN, Hedley DW. Antitumour activity of a potent MEK 
inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary 
pancreatic cancer xenografts. BMC Cancer. 2010;10(1):515. 
213. Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, et al. Allosteric 
MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits 
Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma. 
Neoplasia (New York, NY). 2013;15(10):1161-71. 
214. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, et al. Expression 
profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 2003;21(6):635-7. 
215. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, et 
al. Short interfering RNAs can induce unexpected and divergent changes in the levels of 
untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A. 2004;101(7):1892-7. 
216. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow 
cytometry. Nat Protocols. 2006;1(3):1458-61. 
217. Kajstura M, Halicka HD, Pryjma J, Darzynkiewicz Z. Discontinuous fragmentation of 
nuclear DNA during apoptosis revealed by discrete "sub-G1" peaks on DNA content 
histograms. Cytometry A. 2007;71(3):125-31. 
218. Tsaousis KT, Kopsachilis N, Tsinopoulos IT, Dimitrakos SA, Kruse FE, Welge-
Luessen U. Time-dependent morphological alterations and viability of cultured human 
trabecular cells after exposure to Trypan blue. Clin Exp Ophthalmol. 2013;41(5):484-90. 
219. Chan LL-Y, Kuksin D, Laverty DJ, Saldi S, Qiu J. Morphological observation and 
analysis using automated image cytometry for the comparison of trypan blue and fluorescence-
based viability detection method. Cytotechnology. 2015;67(3):461-73. 
220. Chu VT, Weber T, Graf R, Sommermann T, Petsch K, Sack U, et al. Efficient generation 
of Rosa26 knock-in mice using CRISPR/Cas9 in C57BL/6 zygotes. BMC Biotechnology. 
2016;16:4. 
221. Nakao H, Harada T, Nakao K, Kiyonari H, Inoue K, Furuta Y, et al. A possible aid in 
targeted insertion of large DNA elements by CRISPR/Cas in mouse zygotes. Genesis. 
2016;54(2):65-77. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
72 
 
222. Shin S-E, Lim J-M, Koh HG, Kim EK, Kang NK, Jeon S, et al. CRISPR/Cas9-induced 
knockout and knock-in mutations in Chlamydomonas reinhardtii. Scientific Reports. 
2016;6:27810. 
223. Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, Ploegh HL. 
Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of 
nonhomologous end joining. Nat Biotech. 2015;33(5):538-42. 
224. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic Interaction Between NRAS and 
BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma. The Journal of investigative 
dermatology. 2004;122(2):337-41. 
225. Won J-K, Yang HW, Shin S-Y, Lee JH, Heo WD, Cho K-H. The crossregulation 
between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK 
inhibitor. Journal of Molecular Cell Biology. 2012;4(3):153-63. 
226. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell 
Death Differ. 2009;16(3):368-77. 
227. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. 
Oncogene. 2004;23(16):2838-49. 
228. Cai B, Chang SH, Becker EB, Bonni A, Xia Z. p38 MAP kinase mediates apoptosis 
through phosphorylation of BimEL at Ser-65. J Biol Chem. 2006;281(35):25215-22. 
229. Zhang HH, Pang M, Dong W, Xin JX, Li YJ, Zhang ZC, et al. miR-511 induces the 
apoptosis of radioresistant lung adenocarcinoma cells by triggering BAX. Oncol Rep. 
2014;31(3):1473-9. 
230. Raingeaud J, Whitmarsh AJ, Barrett T, Dérijard B, Davis RJ. MKK3- and MKK6-
regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal 
transduction pathway. Molecular and Cellular Biology. 1996;16(3):1247-55. 
231. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. MKK7 is an essential 
component of the JNK signal transduction pathway activated by proinflammatory cytokines. 
Genes & Development. 2001;15(11):1419-26. 
232. Zhang Z, Zhou X, Shen H, Wang D, Wang Y. Phosphorylated ERK is a potential 
predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an 
in vitro study. BMC Medicine. 2009;7:41-. 
233. Browne AJ, Göbel A, Thiele S, Hofbauer LC, Rauner M, Rachner TD. p38 MAPK 
regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Cell Death & 
Disease. 2016;7(2):e2119. 
234. Donnelly SM, Paplomata E, Peake BM, Sanabria E, Chen Z, Nahta R. P38 MAPK 
contributes to resistance and invasiveness of HER2-overexpressing breast cancer. Current 
medicinal chemistry. 2014;21(4):501-10. 
235. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. p38alpha 
suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat 
Genet. 2007;39(6):741-9. 
236. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, et al. p38alpha 
MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat 
Genet. 2007;39(6):750-8. 
237. Gupta J, del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, Gorgoulis VG, et al. 
Dual function of p38alpha MAPK in colon cancer: suppression of colitis-associated tumor 
initiation but requirement for cancer cell survival. Cancer Cell. 2014;25(4):484-500. 
238. Kumar B, Koul S, Petersen J, Khandrika L, Hwa JS, Meacham RB, et al. p38 mitogen-
activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by 
modulation of MMP-2 and MMP-9 activity. Cancer Res. 2010;70(2):832-41. 
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
 
73 
 
239. Yoshizuka N, Chen RM, Xu Z, Liao R, Hong L, Hu W-Y, et al. A Novel Function of 
p38-Regulated/Activated Kinase in Endothelial Cell Migration and Tumor Angiogenesis. 
Molecular and Cellular Biology. 2012;32(3):606-18. 
240. Bulavin DV, Fornace AJ, Jr. p38 MAP kinase's emerging role as a tumor suppressor. 
Adv Cancer Res. 2004;92:95-118. 
241. Estrada Y, Dong J, Ossowski L. Positive crosstalk between ERK and p38 in melanoma 
stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res. 2009;22(1):66-76. 
242. Offit K. Personalized medicine: new genomics, old lessons. Human Genetics. 
2011;130(1):3-14. 
243. Khattak M, Fisher R, Turajlic S, Larkin J. Targeted therapy and immunotherapy in 
advanced melanoma: an evolving paradigm. Therapeutic Advances in Medical Oncology. 
2013;5(2):105-18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXES
Characterization of TRIB2-mediated resistance to pharmacological inhibition of MEK  
I 
 
ANNEX A- E.Z.N.A Total RNA Kit (Omega) Protocol 
Principle 
The E.Z.N.A.® Total RNA Kits utilized the reversible binding properties of HiBind® matrix, 
a new silica-based material, combined with the speed of mini-column spin technology to 
provide a fast and easy way for isolating total cellular RNA from cultured cells or animal 
tissues.  A specifically formulated high salt buffer system allows more than 100 µg of RNA 
molecules greater than 200 bases to bind to the matrix.  Cells or tissues are first lysed and 
homogenized under denaturing conditions that practically inactivate RNases.  After adjust the 
binding condition by add ethanol, samples are then applied to the HiBind® spin columns to 
which total RNA binds, while cellular debris and other contaminants are effectively washed 
away.  High quality RNA is finally eluted in DEPC-treated sterile water. 
Procedure:  
1. Lyse cells or tissues with 350µl of TRK Lysis Buffer. Remember to add 20µl of 2-
mercaptoethanol per 1 ml of TRK Lysis Buffer before use.  
350µl of TRK Lysis Buffer is sufficient for# 5 x 106 cells or approximately 20 mg disrupted 
tissue (~3 mm cube).  For difficult tissues, more than 5 x 106 cells, or greater than 20 mg tissue, 
use 700 µl of TRK Lysis Buffer.  However, use no more than 30 mg tissue.  
For tissue culture cells grown in monolayer (fibroblasts, endothelial cells, etc.), lyse the cells 
directly in the culture vessel as follows. Aspirate culture medium completely and add TRK 
Lysis Buffer directly to the cells. Use 700µl for T35 flasks or 10 cm dishes, and 350µl for 
smaller vessels. Pipette buffer over entire surface of vessel to ensure complete lysis. Transfer 
lysate to a clean 1.5 ml microfuge tube and proceed to step 2 below. (This method is preferable 
to trypsinization followed by washing because it minimizes RNA degradation by nuclease 
contamination.) 
For cells grown in suspension cultures, pellet cells at no greater than 1,500 rpm (400 x g) for 5 
min. Discard supernatant, add TRK Lysis Buffer, lyse by vortex or pipetting up and down, and 
transfer to a clean 1.5 ml microfuge tube. Proceed to step 2. 
For tissue samples, homogenize using one of the methods discussed on page 4.  For fatty tissues 
such as brain or adipose tissues, please use E.Z.N.A.® Total RNA Kit II (Product # R6934). 
For fibrous sample such as sample for muscle or heart, use protocol B in this user manual. Also 
OBI offers special designed kit for fibrous tissues (Product # R6688).  Unless using liquid 
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nitrogen, homogenize samples directly in TRK Lysis Buffer/2-mercaptoethanol and                        
proceed to step 2. 
2. Add an equal volume (350 µl or 700 µl) 70% Ethanol to the lysate and mix thoroughly by 
vortexing.  
3. Apply sample onto HiBind® RNA spin column. The maximum capacity of the spin cartridge 
is 750 ml. (Larger volumes can be loaded successively.)  A precipitate may form on addition of 
ethanol in step 2. Vortex and add the entire mixture to the column. With the spin column inside 
a 2ml collecting tube (supplied with kit), centrifuge at 10,000 x g for 15 seconds at room 
temperature.  Discard flowthrough and collection tube. 
4. Place column in a clean 2ml collection tube, and add 300 µl RNA Wash Buffer I. Centrifuge 
and discard flow-through.  Reuse the collection tube in step 6. If on-membrane DNase I 
digestion is desired, proceed step 5, otherwise go to step 6. 
5. DNase digestion (Optional) Since HiBind® RNA resin and spin-column technology actually 
removes most of DNA without the DNase treatment, it is not necessary to do DNase digestion 
for most downstream applications. However, certain sensitive RNA applications might require 
further DNA removal. Following steps provide on-membrane DNase I digestion:( see DNase I 
cat.# E1091for detail information) 
a. For each HiBind® RNA column, prepare the DNase I digestion reaction mix as follows: 
 
 
 
 
 
 
 
  
 
b. Pipet 75 µl of the DNase I digestion reaction mix directly onto the surface of HiBind® RNA 
resin in each column. Make sure to pipet the DNase I digestion reaction mixture directly onto 
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the membrane. DNase I digestion will not be completed if some of the mix stick to the wall or 
the O-ring of the HiBind® RNA column. 
c. Incubate at room temperature(25-30NC) for 15 minutes 
6. Place column in a 2ml collection tube, and add 500 µl RNA Wash Buffer I. (If on-membrane 
DNase digestion was performed in the previous step, wait at least 5 minutes before proceeding).  
Centrifuge and discard flow-through. 
7. Place column in the same 2ml collection tube, and add 500 µl RNA Wash Buffer II diluted 
with ethanol. Centrifuge and discard flow-through. Reuse the collection tube in step 8. 
Note: Wash Buffer II Concentrate must be diluted with absolute ethanol before use.  Refer to 
label on bottle for instruction. 
8. Wash column with a second 500 µl of Wash Buffer II as in step 7. Centrifuge and discard 
flow-through. Then with the collection tube empty, centrifuge the spin cartridge for 1 min at 
full speed to completely dry the HiBind® matrix. 
9. Elution of RNA. Transfer the column to a clean 1.5 ml microfuge tube (not supplied with 
kit) and elute the RNA with 50-100 µl of DEPC-treated water (supplied with kit). Make sure to 
add water directly onto column matrix.  Centrifuge 1 min at maximum speed.  A second elution 
may be necessary if the expected yield of RNA >50 µg.  Alternatively, RNA may be eluted 
with a greater volume of water. While additional elutions increase total RNA yield, the 
concentration will be lowered since more than 80% of RNA is recovered with the first elution. 
Pre-heating the water to 70oC before adding to column and incubating column 5 min at room 
temperature before centrifugation may increase yields.  
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ANNEX B- NZY First Strand CDNA Synthesis Kit 
 
Description 
The NZY First-Strand cDNA Synthesis Kit is a system that includes all the necessary 
components to synthesize firststrand cDNA, except template RNA.   
The resulting single-stranded cDNA is suitable for use in realtime quantitative Reverse 
Transcription PCR (RT-qPCR). NZY First-Strand cDNA Synthesis Kit is formulated to provide 
high yields of full-length cDNA products and to increase sensitivity in RT-qPCR. 
 
 
 
 
 
 
 
 
 
Protocol 
1. On ice, add the following reaction components into a sterile, nuclease-free 
microcentrifuge tube (for multiple reactions, a master mix without RNA may be 
prepared): 
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2. Mix gently and incubate at 25 °C for 10 min.  
 3. Incubate at 50 °C for 30 min.  
 4. Inactivate the reaction by heating at 85 °C for 5 min, and then chill on ice.  
 5. Add 1 µL of NZY RNase H (E.coli ) and incubate at 37 °C for 20 min.  
 6. Use the cDNA product directly in PCR or qPCR diluted in TE buffer or undiluted; 
or store at -20 °C until required. 
 
Important notes   
 High quality intact RNA, free of residual genomic DNA and RNases is essential for 
full-length, high quality cDNA synthesis and accurate RNA quantification. For this 
reason, special precautions should be taken when working with RNA:  
 o Aseptic conditions should be maintained: always wear gloves; change gloves 
whenever you suspect 
that they are contaminated; use RNase-free tubes and pipet tips; designate a special area 
and equipment for RNA work only. o DNase I (not provided) may be used to eliminate 
genomic DNA contamination from the starting total RNA.  o The template RNA should 
be stored at -70 °C. Avoid multiple freeze/thaw cycles of RNA.   
  This kit does not include control RNA.  
  Keep all reagents of the kit on ice while setting up the reactions.  
  When performing RT-qPCR using the synthesized cDNA as template, no more than 
1/10 of the final PCR volume should be derived from the reverse-transcription product. 
For instance, use up to 5 µL of cDNA obtained in the firststrand synthesis in a 50 µL 
PCR reaction. 
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ANNEX C- Antibodies list 
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ANNEX D- Plasmids used in shRNA technique 
D.1- shGFP 
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D.2- shTRIB2 1 
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D.3- shTRIB2 2 
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D.4- shTRIB2 3 
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D.5- shTRIB2 4 
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D.6- shTRIB2 5 
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ANNEX E- Annexin V/ PI Apoptosis Detection Kit: SC-4252 AK 
 
The AnnexinV apoptosis detection kit includes the reagents required for identifying a 
population of cells that have initiated apoptosis using a simple staining procedure and analysis 
by fluorescence microscopy or flow cytometry. 
Analysis of samples can be done on live cells and does not require cell fixation. Normal viable 
cells in culture will stain negative for Annexin V FITC and negative for PI. Cells that are 
induced to undergo apoptosis will stain positive for Annexin V FITC and negative for PI as 
early as 1 hour after stimulation. Both cells in later stages of apoptosis and necrotic cells will 
stain positive for Annexin V FITC and PI. 
 
 
 
 
 
 
Protocol: 
1. Induce apoptosis according to the desired method. 
2. Collect supernatant. Wash with PBS 1X, collect supernatant. Trypsinize cells and 
transfer cells to a 15mL conical tube. Pellet cells by low speed centrifugation at 1500 
rpm for 5 minutes. Wash cells once with PBS and ressuspend pellet in 500 µL 1X Assay 
Buffer. 
3. Transfer 100µL aliquot of cells 1 x 105 cells to a 5mL flow cytometry tube.  
4. To cell samples add 1µL of Annexin V FITC and 10µL of Propidium Iodite (PI) per 
100µL cell samples. 
5. Vortex samples gently and incubate 15 minutes at room temperature, in the dark. 
6. Add 400 µL of 1X Assay Buffer to each tube. 
7. Analyze samples using a single laser emitting light at 488 nm for FITC.  
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Reccomended Negative Controls:  
a. No Annexin V / No PI 
b. Annexin V alone 
c. PI alone 
ANNEX E- PI Protocol 
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ANNEX F- Propidium Iodide Protocol 
 
1. Harvest cells in the appropriate manner, and wash in PBS 1X. 
2. Fix in cold 70% Etanol (EtOH). Add dropwise to the cell pellet while vortexing to 
minimize clumpling. 
3. Let the cells fix at least for 30minutes at 4ºC (Samples can be left at this stage for several 
weeks). 
4. To make sure that only DNA is stained, treat samples with Ribonuclease (50µL of 
100µg/mL RNAse). 
5. Add 200 µL of PI (50µg/mL). 
6. Analyze samples by flow cytometry (PI is excited at 488nm laser and emission of 
fluorescence is collected above 580nm.  
 
Note: Phosphate Buffer is composed of 192 parts of 0.2M Na2HPO4 and 8 parts of 0.1M citric 
acid (pH 7.8) 
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ANNEX G: MAPK Pathways 
 
 
Figure G1. The three main subgroups of MAPK ERKS, JNKs and p38-
MAPKs. 
